

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

ERS Clinical Practice Guidelines: High-flow nasal cannula in acute respiratory failure

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Oczkowski, S., Ergan, B., Bos, L., Chatwin, M., Ferrer, M., Gregoretti, C., et al. (2022). ERS Clinical Practice Guidelines: High-flow nasal cannula in acute respiratory failure. EUROPEAN RESPIRATORY JOURNAL, 59(4), 1-18 [10.1183/13993003.01574-2021].

Availability: This version is available at: https://hdl.handle.net/11585/850739 since: 2022-02-01

Published:

DOI: http://doi.org/10.1183/13993003.01574-2021

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/). When citing, please refer to the published version.

(Article begins on next page)



EUROPEAN RESPIRATORY journal

FLAGSHIP SCIENTIFIC JOURNAL OF ERS

Early View

Task force report

ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure

Simon Oczkowski, Begüm Ergan, Lieuwe Bos, Michelle Chatwin, Miguel Ferrer, Cesare Gregoretti, Leo Heunks, Jean-Pierre Frat, Federico Longhini, Stefano Nava, Paolo Navalesi, Aylin Ozsancak Uğurlu, Lara Pisani, Teresa Renda, Arnaud W. Thille, João Carlos Winck, Wolfram Windisch, Thomy Tonia, Jeanette Boyd, Giovanni Sotgiu, Raffaele Scala

Please cite this article as: Oczkowski S, Ergan Büm, Bos L, *et al*. ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure. *Eur Respir J* 2021; in press (https://doi.org/10.1183/13993003.01574-2021).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org

ERS Clinical Practice Guidelines: High-flow nasal cannula in acute respiratory failure

Authors

Simon Oczkowski^{1,2},* Begüm Ergan³,* Lieuwe Bos^{4,5}, Michelle Chatwin⁶, Miguel Ferrer⁷, Cesare Gregoretti^{8,9}, Leo Heunks¹⁰, Jean-Pierre Frat ^{11,12}, Federico Longhini¹³, Stefano Nava^{14,15}, Paolo Navalesi^{16,17}, Aylin Ozsancak Uğurlu¹⁸, Lara Pisani^{14,15}, Teresa Renda¹⁹, Arnaud W. Thille^{11,12}, João Carlos Winck²⁰, Wolfram Windisch²¹, Thomy Tonia²², Jeanette Boyd²³, Giovanni Sotgiu²⁴, Raffaele Scala²⁵

*co-first authors

Affiliations

- Department of Medicine, Division of Critical Care, McMaster University, Hamilton, Ontario, Canada
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
- Department of Pulmonary and Critical Care, Dokuz Eylul University School of Medicine, Izmir, Turkey
- Department of Intensive Care & Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Amsterdam UMC, location Academic Medical Center, Amsterdam
- Respiratory Medicine, Amsterdam UMC, location Academic Medical Center, Amsterdam, The Netherlands.
- Academic and Clinical Department of Sleep and Breathing and NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, Sydney Street, London, UK.

- Dept of Pneumology, Respiratory Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBERES, Barcelona, Spain.
- Department of Surgical, Oncological and Oral Science University of Palermo, Palermo, Italy.
- 9. G.Giglio Institute, Cefalu', Italy
- Department of Intensive Care Medicine, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
- Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
- INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.
- Anesthesia and Intensive Care Unit, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
- Alma Mater Studiorum University of Bologna, Dept of Clinical, Integrated and Experimental Medicine (DIMES), Bologna, Italy
- 15. Respiratory and Critical Care, Sant'Orsola Malpighi Hospital, Bologna, Italy
- 16. Institute of Anesthesia and Critical Care, University Hospital, Padua, Italy
- Anesthesia and Critical Care, Department of Medicine-DIMED, University of Padua, Padua, Italy
- 18. Department of Pulmonary Medicine, Baskent University, Istanbul, Turkey.
- Cardiothoracic and Vascular Department, Respiratory and Critical Care Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.
- 20. Faculdade de Medicina da Universidade do Porto, Portugal.
- Cologne Merheim Hospital, Dept of Pneumology, Kliniken der Stadt Köln, gGmbH,
 Witten/Herdecke University, Faculty of Health/School of Medicine, Köln, Germany.

- 22. Institute of Social and Preventive Medicine, University of Bern, Switzterland
- 23. European Lung Foundation (ELF), Sheffield, United Kingdom
- Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical, Experimental Sciences, University of Sassari, Sassari, Italy.
- 25. Pulmonology and Respiratory Intensive Care Unit, Cardio-Thoraco-Neuro-vascular and Methabolic Department, Usl Toscana Sudest, S Donato Hospital, Arezzo, Italy.

Corresponding author

Raffaele Scala

Pulmonology and Respiratory Intensive Care Unit, Cardio-Thoraco-Neuro-vascular and Methabolic Department, Usl Toscana Sudest, S Donato Hospital, Arezzo, Italy.e-mail address: raffaele_scala@hotmail.com

Abstract

Background

High-flow nasal cannula (HFNC) has become a frequently used non-invasive form of respiratory support in acute settings, however evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF).

Materials and methodology

The European Respiratory Society Task Force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The Task Force used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methods to summarize evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and non-invasive ventilation (NIV) for the management of adults in acute settings with ARF.

Results

The Task Force developed 8 conditional recommendations, suggesting using: 1) HFNC over COT in hypoxemic ARF, 2) HFNC over NIV in hypoxemic ARF, 3)HFNC over COT during breaks from NIV, 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications, 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications, 6) HFNC over COT in non-surgical patients at low risk of extubation failure, 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV, 8) trialling NIV prior to use of HFNC in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic ARF.

Conclusions

HFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of non-invasive respiratory support to provide to patients in different acute settings.

Introduction

HFNC is a respiratory support device, which is used during early non-invasive management of acute respiratory failure (ARF), alongside conventional oxygen therapy (COT), and noninvasive ventilation (NIV). Benefits of HFNC, which are both clinical (e.g., patient comfort and ease of use) and physiological (e.g., high oxygenation, alveolar recruitment, humidification and heating, increased secretion clearance, reduction of dead space) (1), can prevent deterioration of lung function and endotracheal intubation (2-4). However, there is limited evidence on the most appropriate form of non-invasive respiratory support in the different ARF scenarios. While HFNC is more comfortable and tolerated when compared to COT and to NIV, its ability to unload respiratory muscles in ARF may be lower than that provided by NIV. Moreover, prolonging non-invasive respiratory support in patients failing with either HFNC and NIV may result in delayed intubation and worsen hospital mortality (2, 5). Risks and benefits may vary in different scenarios (e.g., hypoxemic and hypercapnic ARF, post-operative and post-extubation ARF, coronavirus disease 2019 [COVID-19] pneumonia).

The European Respiratory Society (ERS) created a Task Force (TF) to provide evidence-based recommendations on HFNC in adults with ARF.

Materials and Methods

Scope and purpose of the document

This document is intended to help clinicians, policy-makers and patients in making evidence-based decisions on HFNC in adults with ARF in different settings. For the most part, the perspective of individual clinicians in high-resourced settings was considered, being reflective of the ERS membership. Nevertheless, feasibility of HFNC in lower-resourced countries has been considered **(Table 1)** (6). Due to limitations in the certainty of evidence and the variation in available resources, all recommendations were weak/conditional.

Composition of the TF panel

The TF consisted of 18 clinicians with expertise in respiratory and acute care medicine. The leadership team consisted of clinical chairs (B. Ergan, R. Scala) along with the methodology team (S. Oczkowski, G. Sotgiu) and ERS methodologist (T. Tonia) who had experience in guidelines development using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. The European Lung Foundation (ELF) provided a representative to give a patient perspective.

Conflict of interest declaration and management

All TF members were required to disclose any financial conflicts and sign a confidentiality agreement in accordance with the ERS policy.

Formulation of questions

An initial list of eight questions was developed by the TF chairs (BE, RS) and submitted to ERS for approval. The questions were structured in PICO (population; intervention; comparison; outcomes) format and, together with a list of outcomes, were approved by the TF panelists and the methodology team **(Table 2).** The TF planned two *a priori* subgroups: for PICO questions on hypoxemic respiratory failure: immunocompetent and immunocompromised patients. With the advent of the COVID-19 pandemic in March 2020, the TF included a third subgroup: COVID-19 patients.

Literature searches

With the assistance of a medical librarian, the methodology team conducted systematic searches of the medical literature. We searched up to January 2021 in MEDLINE, Embase (database inception onwards) and Cochrane CENTRAL (2006 onwards) for relevant observational studies and randomized clinical trials (RCTs). (supplementary material - search strategy and results)

The retrieved references were screened in duplicate using Covidence reference management software.(7) We included English-language RCTs and observational studies comparing HFNC to COT or NIV. **(supplemental Figure S1)** Data was extracted into a pilot-tested data extraction form, and entered into Revman v.5.3 software for meta-analysis.(8) For each PICO question the methodology team, with input from the TF chairs, rated the certainty of evidence for each outcome using standard GRADE methods and created evidence summaries.(9, 10) Certainty of evidence was rated as "high," "moderate," "low," or "very low" with RCTs starting as "high" certainty and observational evidence as "low" certainty.(11) Evidence could be rated down one or two levels based upon whether the included studies were judged to be at high risk of bias,(12) results were inconsistent between studies,(13) the evidence was indirect,(14) imprecise,(15), or at high risk of publication bias.(16) The TF was asked to prioritize the initial list of outcomes, rating their clinical importance from 1-9, with mean scores of 1-3 indicating "low importance", 4-6 "important but not critical," and 7-9 as "critical".(17) The panel prioritized as "critical" mortality, intubation, and escalation of treatment.

A virtual meeting was held during the ERS Congress in September 2020 to discuss PICOs and the literature search results. The leadership team met virtually in November 2020 to work through the GRADE evidence-to-decision (EtD) framework and develop draft recommendations. The EtD framework considers balance of desirable and undesirable effects, certainty of effects, patient values and preferences, resource use, cost-effectiveness, health equity, and acceptability and feasibility of an intervention in order to develop an overall recommendation.(18) Recommendations were designated as "weak/conditional" or "strong," using the wording "we suggest" and "we recommend," respectively.(19) The TF panel reviewed the evidence and draft recommendations, and voted on both using the GRADEPro PanelVoice system between December 2020 and January 2021.(20) For a weak/conditional recommendation a majority vote was sufficient to approve the recommendation; for a strong recommendation, stronger agreement (>70%) was required. Questions for which consensus were not reached were re-evaluated by the leadership team based upon feedback from the TF, revised, and had additional rounds of voting to reach consensus.

Results

All recommendations had consensus except for PICO questions #7 and #8, for which a second round of voting was conducted. Evidence summaries (including forest plots from meta-analyses) and Evidence-to-Decision Framework summaries for each PICO can be found in the supplementary material.

HFNC FOR HYPOXEMIC ACUTE RESPIRATORY FAILURE

PICO Question 1: Should HFNC or COT be used in patients with acute hypoxemic respiratory failure?

1.

Recommendation 1: We suggest the use of HFNC over COT in adults acute hypoxemic respiratory failure (conditional recommendation, moderate certainty of evidence).

Background

Acute hypoxemic respiratory failure (AHRF) is caused by a wide range of etiologies including pulmonary infection, inflammation, or exacerbation of chronic heart or lung disease. The clinical spectrum of AHRF ranges from mild hypoxemia to full-blown acute respiratory distress syndrome (ARDS). In this question de-novo AHRF was addressed, rather than established ARDS, as there is not yet consensus on whether non-intubated patients can be diagnosed with ARDS.(21) Non-invasive respiratory support aims to improve hypoxemia, reduce work of breathing, enhance comfort, avoid intubation, and provide time to effectively treat the triggering condition, thereby reducing mortality.(22) Unfortunately, many patients with AHRF require escalation to invasive mechanical ventilation (IMV). (23) The most common non-invasive respiratory treatment in AHRF is COT, which increases the fraction of inspired oxygen (FiO₂), using simple interfaces including nasal prongs, facemask with reservoirs, or Venturi mask. Potential mechanisms of COT failure include ineffective support matching patient ventilatory needs due to altered respiratory mechanics, unreliable FiO2 delivery, lack of humidification, and patient self-inflicted lung injury (P-SILI).(24, 25) HFNC is a non-invasive, high concentration oxygen delivery interface which addresses some of the limitations of COT. By providing airflows as high as 50–60 litres/minute, HFNC closely matches the inspiratory demands of dyspneic patients with AHRF, and reliably achieves an FiO₂ as high as 100%, while also providing a low level of positive end-expiratory pressure (PEEP) in the upper airways, facilitating alveolar recruitment. (2) Other potential benefits of HFNC over COT include decreased risk of P-SILI avoiding harmful changes in trans-pulmonary pressure, carbon dioxide (CO2) washout of upper airways, improved ventilation; and provision of reliable humidification, which may result in increased patient comfort and enhanced secretion clearance.(1, 26-28) These clinical and physiologic benefits constitute a strong rationale for early use of HFNC to prevent the need of non-invasive and invasive positive-pressure ventilation, and to reduce the risk of mortality mostly correlated with ventilator-associated complications. This is particularly true for immunocompromised patients who are more likely to develop complications correlated to IMV, such as ventilatorassociated pneumonia (VAP).(29, 30)

Evidence Summary

12 parallel-group RCTs (31-42) and 4 cross-over RCTs (27, 43-45) comparing HFNC to COT were selected. In general, the evidence is limited by imprecision. Mortality is similar in the short term (hospital, intensive care unit [ICU], or 28 days) (RR 0.99, 95% CI 0.84-1.17; RD - 0.3% 95%CI -4.1 to 4.3; moderate certainty) or 90 days (RR 0.97, 95% CI 0.83-1.13; RD -1.0, 95%CI -5.7 to 4.4; moderate certainty). 11 studies evaluated the effect of HFNC on intubation, finding that HFNC may reduce intubation (RR 0.89, 95% CI 0.77-1.02; RD -3.1%,

95% CI -6.4 to 0.6; moderate certainty) and escalation to NIV (RR 0.76, 95%CI 0.43 to 1.34; RD -2.9%, 95%CI -6.9 to 4.1, moderate certainty).(32-38, 40-42) HFNC reduces patient discomfort (SMD 0.54 lower, 95% CI 0.86 lower to 0.23 lower; high certainty), dyspnea (SMD 0.32 lower, 95% CI 0.66 lower to 0.03 higher; moderate certainty), and slightly lowers respiratory rate (MD 2.25 RPM, 95%CI 3.24 lower to 1.25 lower; high certainty). The impact of HFNC upon gas exchange is generally small, with HFNC increasing partial pressure of oxygen in arterial blood (PaO₂) values (MD 16.72 mmHg, 95% CI 5.74 higher to 27.71 higher; high certainty) and, possibly, the ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen (PaO₂/FiO₂) (MD 25.01 mmHg, 95% CI 14.21 lower to 64.24 higher; low certainty); without a substantial effect on PaCO₂ values (MD 0.01 mmHg, 95% CI 1.17 lower to 1.2 higher, high certainty).

Impact upon length of stay is inconsistent, suggesting an increased ICU stay by 1.97 days (95% CI 1.02 higher to 2.93 higher, moderate certainty), with a small overall reduction in hospital length of stay of 0.72 days (95% CI 1.54 lower to 0.1 higher, moderate certainty). For the subgroup of immunocompromised patients, effects are similar, with no impact upon mortality, (33, 34, 38, 42) although without the reduced intubation rate between HFNC and COT. No RCTs evaluating HFNC vs. COT in patients with COVID-19 were found.

Justification

The guideline TF panel makes a conditional recommendation for HFNC over COT as the evidence suggested that the balance of effects, particularly a reduction in intubation, likely favors HFNC over COT. However, the panel's certainty is limited by imprecision. The impact on mortality is likely small (<1%). Thus, HFNC is most likely to benefit patients who are at high risk of intubation; its use should be favored in patients with more severe disease rather than patients requiring low oxygen flow rates, or in those with severe symptoms, given the improvements in patient comfort, dyspnea, respiratory rate, and gas exchange. The panel

notes that AHRF, particularly ARDS, is heterogenous: identifying patients most likely to benefit from HFNC requires clinician judgment.(46)

The TF does not identify any major tradeoffs in which patient values would likely play a role, as both the increased comfort of HFNC along with lower intubation rates would likely be preferred by most patients.

There is limited evidence on resource utilization. While material cost, set-up, and oxygen use of HFNC are likely higher than COT, avoiding intubation may save money and ancillary costs (ie, sedation, ventilators, monitors). On the other hand, during times of resource scarcity other considerations (avoiding intubation vs. limiting oxygen vs. human resources) may influence the choice of HFNC versus. COT. While the existing evidence suggests an increased ICU length of stay, the panel is uncertain as hospital policies differ whether or not HFNC requires ICU, intermediate care and respiratory high-dependency unit (stepdown/step-up unit), or general ward. (47) Overall hospital length of stay may be unaffected by use of HFNC. TF identified one study evaluating cost-effectiveness of HFNC in the preintubation phase in the UK.(48) It found that HFNC resulted in overall cost-savings of £156 compared to COT, and higher savings of £727 in high-risk patients. In low-income countries HFNC may reduce health equity (e.g., the device may not be available to all persons, and high oxygen use by HFNC may limit availability of oxygen to other patients). Widespread use of HFNC in ICUs demonstrates feasibility of the device, even in resource-constrained settings during a pandemic.(49)

Subgroup considerations

Data for both immunocompetent and immunocompromised subgroups were estimated and similar for mortality, but showing a smaller magnitude for intubation and escalation to NIV in the immunocompromised subgroup. There is no evidence of increased harm in the use of HFNC VS. COT. Given this residual uncertainty, the panel decided there is insufficient data to make a separate recommendation.

There is little high-quality data to guide effectiveness of HFNC in COVID-19, however, given the heterogeneity of patients which may include other viral pneumonias and ARDS, it is reasonable to make the same conditional recommendation. Use of HFNC requires separate consideration of resources, including protective personal equipment (PPE) and ventilation, given the currently unknown risks of transmissibility from patients using HFNC versus COT.(50-53) The panel does not make a recommendation regarding the use of awake prone position in HFNC, recognizing there is little evidence and RCTs to address the question.(54-57)

PICO Question 2: Should HFNC or NIV be used in patients with acute hypoxemic respiratory failure?

Recommendation 2: We suggest the use of HFNC over NIV in patients with acute hypoxemic respiratory failure (conditional recommendation, very low certainty of evidence). Background

HFNC and NIV are used more frequently in patients with progressive or moderate to severe AHRF (PaO₂/FiO₂ \leq 200 mmHg), when the risks of intubation and death are higher.(23, 24). In more severe AHRF (PaO₂/FiO₂ <100), clinicians aim to balancing the benefits of maintaining spontaneous breathing and averting intubation together with its complications (*i.e.*, VAP and ventilator-induced lung injury [VILI]) versus. the harms of delayed intubation, including high inspiratory effort, increased lung stress, and risk of lung injury during non-invasive respiratory support.(58) HFNC is an attractive alternative to NIV for treating patients with AHRF and high respiratory demand.

While NIV provides higher mean airway pressures than HFNC and assists ventilation by effectively unloading respiratory muscles, treatment failure is frequent. NIV failure occurs more likely in patients with more severe ARF: PaO₂/FiO₂ <200 mmHg before treatment and higher SAPSII (>35) are associated with a two-fold risk of intubation.(59) Improvement in gas exchange provided by NIV may help identify patients at greatest risk of treatment failure,

as PaO₂/FiO₂ <175 mmHg after one hour of NIV is associated with need for intubation.(23) Finally, expired tidal volume exceeding 9-9.5 ml/Kg of predicted body weight while undergoing NIV delivered in pressure support mode (PSV) with a low level of assistance can predict treatment failure with good specificity and sensitivity.(60, 61)

There are practical differences between HFNC and NIV which may impact patient comfort and tolerance. While HFNC devices use a similar interface, NIV can be delivered using either a facemask or helmet interface. To date, the most frequently used interface in RCTs has been face mask NIV, although helmet NIV may be more comfortable and allow the application of a more "protective" ventilation with higher PEEP (*i.e.*, 8-12 cmH2O) and lower pressure support values with fewer air leaks and interruptions.(62, 63) Clinicians now have the option of HFNC and NIV with a variety of interfaces for use in AHRF; however, the recent ERS/ATS TF did not offer a recommendation on the use of NIV for de novo AHRF, noting that the majority of the studies used COT as a comparator.(23)

Evidence summary

We identified 5 parallel-group RCTs (33, 64-67) and 2 crossover RCTs (68, 69) comparing HFNC to NIV in AHRF. Three RCTs reported short-term mortality (hospital, ICU, or 28-day), finding that HFNC may reduce mortality (RR 0.77, 95%CI 0.52 to 1.14; RD -4.5%, 95%CI -9.4 to 2.7; very low certainty); however, this is limited by imprecise and inconsistent effects between the studies. One trial reported a possible large reduction in mortality with use of HFNC (RR 0.43, 95%CI 0.25 to 0.78; RD -16.1%, 95%CI -21.4 to -6.2; low certainty). In both, the panel raises concerns that the NIV used does not reflect current real-world practice (lower intensity and duration - only 8 hours/day) and thus the evidence is rated down for indirectness. 5 RCTs evaluated effect of HFNC on intubation, demonstrating that HFNC may reduce intubation (RR 0.84, 95% CI 0.61 to 1.16; RD -4.1%, -10.1 to 4.1; low certainty), but this result is limited by indirectness and imprecision. (33, 64-67)

HFNC may have a small impact on length of stay, potentially decreasing ICU stay by 0.55 days (95% CI -2.0 to 0.89, low certainty) and increasing overall hospital stay by 0.8 days (95% CI -0.59 to 2.19, very low certainty). Pooled analysis of 4 RCTs shows that HFNC may improve patient comfort (SMD -0.23, 95% CI -0.55 to 0.09, moderate certainty) but results in greater degree of perceived dyspnea than NIV (SMD 0.19, 95% CI -0.01 to 0.40, very low certainty).(33, 44, 65,69)

Looking at the physiologic effects of HFNC, pooled analysis of 4 (33,44,67,69) and 3 RCTs (33,67,69) respectively shows that HFNC slightly increases PaO₂ values (MD 19.98 mmHg, 95% CI 11.97 to 28.0, moderate certainty) and PaO₂/FiO₂ ratio (MD 43.26, 95% CI 29.48 to 57.04, moderate certainty), with little difference in PaCO₂ values (MD 0.45 mmHg (95% CI 1.94 lower to 1.05 higher, low certainty) or respiratory rate (MD 0.83 RPM, 95% CI -1.04 to 2.7, low certainty).

Justification

The panel judged that the existing evidence generally supports the use of HFNC over NIV as first-line treatment for AHRF, but this evidence is limited by imprecision, and there is still uncertainty as to the true effect of NIV, given concerns about the indirectness of the comparison NIV as used in the studies. In particular, the trial by Frat *et al.* demonstrated the largest benefit of HFNC, but NIV had short therapeutic time (8 hours per day), and lower levels of PEEP than those commonly prescribed (especially with helmet interface) and possibly no humidification used in the NIV arm.(33) Additionally, the included studies generally used facemask which may not be as well tolerated.(70) Therefore, the TF rates down all outcomes for indirectness, resulting in very low certainty for critical outcomes. Reassuringly, for almost every outcome (other than dyspnea) HFNC appeared to be beneficial or at least neutral compared to NIV.

The TF acknowledges uncertainty regarding which patients are most likely to benefit from each device. Individual patient factors and clinical decision-making play an important role in choosing which respiratory support should be adopted. While NIV may be relatively contraindicated in some patients (e.g., excessive secretions, facial hair/structure resulting in air leaks, poor compliance), and HFNC the clearly superior option, there may be a subset of patients for whom NIV may be preferable. These may be patients with increased work of breathing, respiratory muscle fatigue, and congestive heart failure, in which the positive pressure of NIV may positively impact hemodynamics. A trial of NIV might be considered for select patients with AHRF, pneumonia, or early ARDS if there are no contraindications and close monitoring by an experienced clinical team who can intubate patients promptly if they deteriorate.(23) In such cases individual clinician judgment is key to choose NIV, interface, and settings.

The TF does not identify any major tradeoffs where patient values may play a role in deciding between HFNC and NIV; almost all outcomes favored HFNC. Overall, the TF's considerations for resource use are similar to those in Recommendation 1, though noted that the actual device and setup for NIV require more resources than COT, making the difference between the two alternatives less pronounced. Resource considerations and cost-effectiveness of HFNC versus NIV may vary between regions.

Subgroup Considerations

Benefits of HNFC may be greater in immunocompromised patients. However, these results are entirely derived from one study and remain imprecise, and judged insufficient for a strong recommendation. The TF choose to make only a single recommendation. No RCTs comparing HFNC to NIV in COVID-19 were available, and the panel choose to not make a separate recommendation. Subsequent to the TF voting, an RCT comparing HFNC to helmet NIV in COVID was published: it found no differences in respiratory support-free days or mortality at 30 or 60 days, but a reduction in intubation at 28 days (OR 0.37; 95%CI 0.17 to 0.82; RD -23%, 95%CI -39 to -5).(71) While suggesting helmet NIV may reduce intubation compared to HFNC in COVID-19, it is interesting that mortality between the groups is unchanged. While this study demonstrates the viability of both devices in COVID-19, further research is needed before a definitive recommendation can be issued, especially as helmet NIV is not available in all centers and such a recommendation would require substantial change in practice for many hospitals.

<u>**PICO</u>** Question <u>3</u>: Should HFNC or COT be used during breaks from NIV in patients with acute hypoxemic respiratory failure?</u>

Recommendation 3: We suggest use of HFNC over COT during breaks from NIV in patients with acute hypoxemic respiratory failure (conditional recommendation, low certainty of evidence)

Background

While NIV is frequently used to treat ARF, breaks from NIV are necessary for practical reasons (feeding, speaking), patient's tolerance (relief from mask pressure), and to ascertain readiness for weaning from NIV. COT is used during these breaks; however, HFNC may be a more effective alternative. Sequential alternating protocols (e.g., sessions of 2h HFNC followed by 1h NIV) may limit the need for prolonged NIV by maintaining adequate oxygenation. In a small (n= 28) prospective single-centre observational study, it was shown that HFNC was better tolerated than NIV and allowed for significant improvement in oxygenation and tachypnea compared with COT.(72) Thus, for patients treated with NIV, it remains open the question of whether COT or HFNC should be prescribed during breaks.

Evidence Summary

One RCT evaluated 47 patients receiving humidified facemask NIV for \geq 24 hours.(73). Half had AHRF, the majority of whom showing a PaO₂/FiO₂ ratio <300. The study was prematurely terminated for slow recruitment rate. Although underpowered to determine differences in intubation rate (2/28 VS. 0/26, p-value: 0.49, very low certainty) the total time spent on NIV between the HFNC and COT groups was similar (1315 (225) minutes VS. 1441 (220) minutes, p-value: 0.07). However, HFNC resulted in better comfort measured with mean±SD visual analogue scores (8.3±2.7 VS. 6.9±2.3), and, during breaks, mean±SD respiratory rate (20.1±4.1 VS. 21.8±5.2) and mean±SD perceived dyspnea (2.1±2.8 VS. 2.4±2.2) were reduced. The frequency of adverse events (e.g., eye irritation, 8% VS. 21.6%) and of difficulty in eating (13.3% VS. 36.2%) were lower with HFNC during breaks compared to COT.

Justification

Given that the direct evidence consisted of a single study, the TF considered indirect evidence from Recommendation 1. Both direct and indirect evidence suggest a small benefit from HFNC over COT during breaks off NIV, with few undesirable effects. The impact upon critical outcomes (e.g., mortality, intubation) is unclear, but likely to be small. Thus, the TF suggests that in the subset of patients with AHRF for whom clinicians and patients choose NIV HFNC may be preferred over COT during breaks. As the potential benefits are small and there is a likely wide variation in resources, these should be the primary factor in deciding whether to prescribe HFNC over COT during breaks from NIV. As the major benefits appear to be linked to patient comfort, rather than to reduction in intubation requirement, the costeffectiveness is likely to be low.

2. HFNC IN POST-OPERATIVE PATIENTS

Background

Post-operative pulmonary complications (PPC) play a significant role in determining patient morbidity, mortality, and length of hospital stay.(74-76) Most frequent during the first 7 days after an operation, PPC range from atelectasis to ARDS. The risk of ARF, likely the most important PPC, is dependent upon many factors including the surgery (e.g., duration of surgery or type of surgical procedure leading to increased post-operative pain or respiratory muscle dysfunction), anesthesia (e.g., general anesthesia), mechanical ventilation (e.g., intra-

operative high tidal volume ventilation), and patient (e.g., age, co-morbidities, and life-style factors). The choice of post-operative respiratory supportive strategies may affect the risk of PPC. COT is the first-line post-operative respiratory therapy, but it does not provide a reliable FiO₂ or a real support for work of breathing. NIV and continous positive airway pressure (CPAP) are second-line respiratory support when COT fails, leading to airway splinting and reduced work of breathing through better respiratory compliance and inspiratory effort.(23) Both NIV and CPAP appear effective in patients with post-operative ARF, especially after abdominal and thoracic surgery. NIV was shown to reduce intubation rate, incidence of nosocomial infections, length of stay, and mortality rates; therefore, official ERS/ATS clinical practice guidelines suggest NIV for patients with post-operative ARF.(23) Other pre-operative guidelines suggest that NIV should be performed by physicians with skill in airway management and ventilation of patients with lung injury.(77) HFNC should be prescribed in hypoxemic patients with poor tolerance of non-invasive respiratory support. Drawbacks of post-operative NIV/CPAP are related to a monitored setting and to the risk of failure due to poor patient tolerance of the positive pressure or interface, or skin breakdown. HFNC may overcome these limitations.(78, 79) These findings are particularly relevant in surgical hypoxemic patients, given the potential for anastomotic leakage and delayed wound healing when positive pressure NIV or mechanical ventilation are applied.(80, 81) COT shows several drawbacks, including insufficient warming and humidification. Because of increased muco-ciliary clearance,(1) augmented dead space washout, and improved pulmonary mechanics, HFNC may be an effective alternative alongside COT and NIV/CPAP in post-operative patients whose hypoxemia is often highly dependent on alveolar collapse.(82)

According to the PPO risk profile (low versus high), two recommendations have been produced comparing HFNC to COT and NIV in posteoperative patients.

<u>**PICO**</u> Question <u>4</u>: Should HFNC or COT be used in post-operative patients after extubation?

Recommendation 4: We suggest the use of either COT or HFNC in postoperative patients at low risk of respiratory complications (conditional recommendation, low certainty of evidence).

Evidence summary

The TF identified 14 RTCs evaluating HFNC in comparison with COT in post-operative patients.(80, 83-95) HFNC likely has little to no effect upon mortality (RR 0.64, 95%CI 0.19 to 2.14; RD -0.5%, 95%CI -1.1 to 1.5; moderate certainty). It may result in small reduction in risk of reintubation (RR 0.66 95%CI 0.23 to 1.91; RD -1.2, 95%CI -2.8 to 3.3; low certainty) and uncertain reduction in risk of escalation to NIV (RR 0.77, 95%CI 0.42 to 1.40; RD -2.6, -6.8 to 4.7; very low certainty). Length of stay in hospital and ICU is reported in 10 and 11 RCTs, respectively, demonstrating that HFNC has little effect on ICU length of stay (MD 0.02 days, 95% CI -0.09 to 0.13; high certainty), and on hospital stay (MD -0.47 days, 95%CI -0.83 to -0.11; high certainty).

HFNC has little effect on discomfort (SMD 0.54 lower, 95% CI -1.12 to 0.05, low certainty), but may result in higher PaO₂/FiO₂ ratio (MD 34.89 mmHg, 95%CI -15.19 to 84.96; moderate certainty) and PaO₂ values (MD 6.2 mmHg, 95%CI 3.58 to 8.28; high certainty); with no significant effect on PaCO₂ values (MD -1.9 mmHg, 95% CI -4.81 to 0.38; high certainty) or respiratory rate (MD -0.14 RPM, 95%CI -0.83 to 0.54; moderate certainty).

Justification

As the evidence was unclear regarding whether the balance of effects favors the routine use of HFNC VS. COT post-operatively, the TF decided on a conditional recommendation for either HFNC or COT in post-operative patients. While point estimates for mortality, reintubation, hospital length of stay, and physiologic variables potentially favor HFNC, the certainty of evidence for critical outcomes (mortality, reintubation, escalation to NIV) is low, limited by imprecision. The following limitations were found: heterogeneity and low event rates, higher prevalence of patients undergoing cardiac and thoracic surgery, different ways of COT application (e.g., low versus high flow face-mask delivery system). As the panel does not identify any significant undesirable clinical effects with HFNC, either would be reasonable; however, in most centers, it is likely that HFNC will cost more and COT would be the preferred respiratory support. The TF did not identify any major tradeoffs where variability of patient values and preferences would impact the use of HFNC.

Even though costs and cost-effectiveness of HFNC and COT will vary between centers, COT may be favored over HFNC in low income countries in terms of limited resource utilization. The panel did not identify any significant elements regarding the acceptability of HFNC. HFNC is likely to be a feasible supportive option in patients after surgery, especially those already planned for admission to a monitored setting.

Clinicians and patients may choose to use HFNC over COT in specific circumstances, based upon patient comfort, perceived risk of pulmonary complications, and resources/availability of devices. Key issues to consider if HFNC is to be chosen over COT are related to patient characteristics (e.g., co-morbidities), surgical variables (*i.e.*, risk of complications), resource considerations (e.g., availability of devices, monitoring, staffing, oxygen), and patient preferences (e.g., comfort, dyspnea, etc.).

PICO Question 5: Should HFNC or NIV be used in post-operative patients after extubation? **Recommendation 5**: We suggest either HFNC or NIV in post-operative patients at high risk of respiratory complications (conditional recommendation, low certainty of evidence). Evidence summary

One trial compared HFNC to NIV in 830 patients with or at high risk of ARF after cardiothoracic surgery.(78) When compared to NIV (≥4hrs/day, PS level at 8 cmH2O, PEEP level at 4 cmH2O, FiO₂ 50%), HFNC (continuous, flow, 50L/min, FiO₂ 50%) may result in a small increase in mortality (RR 1.22, 95%CI 0.72 to 2.09; RD 1.2%, 95%CI -1.5 to 6.0; low certainty), with likely little to no difference in reintubation (RR 1.02, 95%CI 0.73 to 1.44; RD 0.3%, 95%CI -3.7 to 6.0; moderate certainty). HFNC results in little to no difference in length of stay in ICU (MD 0 days, 95% CI -0.6 to 0.6; moderate certainty), or hospital (MD -1 day, 95%CI -2.21 to 0.21, moderate certainty). HFNC has little to no effect upon PaCO₂ values and respiratory rate, but results in a slightly lower PaO₂/FiO₂ ratio (MD -63, 95%CI -80 to -46; high certainty). Skin breakdown is significantly more prevalent with NIV than HFNC after 24 hours.

Justification

The evidence comes from a single trial of patients with or at risk for respiratory failure after cardiothoracic surgery, and patients with other types of surgery are described. While HFNC appears to be similar to NIV, data is limited by imprecision. Point estimate for mortality favors NIV over HFNC, but this is limited by very serious imprecision, which does not exclude neither clinically meaningful benefit nor harm from the use of HFNC. As the desirable and undesirable effects appear to be closely balanced between HFNC and NIV, the TF choose to make a conditional recommendation suggesting that either HFNC or NIV could reasonably be used, based upon individual patient, surgical, and resource considerations. A subgroup analysis of this trial demonstrated similar effects in obese subjects (BMI>30 kg/m2) (n=231).(96)

The TF does not identify any major instances where variation in patient values, acceptability, or feasibility would be likely to impact the use of HFNC VS. NIV for patients planned for admission to a monitored setting. Resources and cost-effectiveness are expected to vary.

3. HFNC TO PREVENT EXTUBATION FAILURE IN NON-SURGICAL PATIENTS

PICO Question 6: Should HFNC or COT be used in non-surgical patients after extubation?

Recommendation 6: We suggest HFNC over COT in non-surgical patients after extubation at low or moderate risk of extubation failure (conditional recommendation, low certainty of evidence).

Background

Extubation remains a challenge in some patients (e.g. presence of weak cough, poor neurologic status, older patients with severe cardiac or respiratory disease) and between 10-20% of attempts at extubation will fail. (97, 98) Re-intubation may lead to prolonged mechanical ventilation and longer ICU stay, increased hospital morbidity and mortality. Sufficient oxygen delivery after extubation is critical to maintain adequate oxygenation. Extubated patients often require elevated inspiratory flow and adequate oxygen administration. HFNC may prevent hypoxemic episodes after extubation, decrease respiratory rate, facilitate removal of secretions, reduce atelectasis, and lead to a higher probability of extubation success when compared to COT. The question is based on the assessment of HFNC as a first-line therapy for ICU patients after extubation.

Evidence summary

Pooled analysis of RCTs (99-110) shows HFNC when compared to COT likely reduces the rate of reintubation (RR 0.62 95% CI 0.38 to 1.01; RD -5.1% 95% CI -8.2 to 0.1%; moderate certainty) and the need for escalation to NIV (RR 0.38 95% CI 0.17 to 0.85; RD -9.4% 95% CI -12.5 to -2.3%; moderate certainty) for ICU patients at risk of respiratory failure after extubation. There is likely no effect on mortality (RR 1.01 95% CI 0.68 to 1.52, RD -0.1 % 95% CI -3.7 to 4.3%, moderate certainty). Lengths of ICU (MD 0.29 days, 95% CI -0.27 to 0.85 days, high certainty) and hospital stay (MD -1.08 days, 95% CI -4.83 days to 2.66, low certainty) are similar for HFNC and COT. HFNC is associated with small improvement in comfort (SMD 0.77 SD, 95% CI 0.03 to 1.5 SD, high certainty) and reduction of respiratory rate (MD -1.98 RPM 95% CI -3.9 to -0.06; high certainty). Gas exchange is not significantly

different exposed to HFNC or COT, (PaO2 MD 7.57 mmHg, 95%CI 2.68 to 12.46, high certainty; PaCO₂ MD 0.15mmHg, 95%CI -1.89 to 1.58 mmHg, high certainty).

Justification

HFNC after extubation in non-surgical patients may reduce reintubation rate and escalation to NIV with no major undesirable side effects. There is no effect on mortality with moderate certainty, limited by imprecision. The TF does not identify any tradeoffs where patient values and preferences would be likely to vary; almost all patients would prefer to avoid reintubation. The major limitation for widespread use of HFNC is accessibility of HFNC and available resources. A UK cost-effectiveness analysis suggested that HFNC is likely costeffective even in patients at low-risk of reintubation.(111) Cost-effectiveness regionally varies, and is probably less for patients at low risk of complications.

<u>PICO</u> Question <u>7</u>: Should HFNC or NIV be used in non-surgical patients after extubation? Recommendation 7: We suggest the use of NIV over HFNC after extubation for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV (conditional recommendation, moderate certainty of evidence).

Background

NIV has been proposed as a method to prevent post-extubation respiratory failure and need for reintubation, especially in patients at high risk of extubation failure. Patients at high risk are those who can develop hypercapnia during the spontaneous breathing trial, those with chronic cardiac and respiratory disorders, with advanced age, and with airway patency problems.(112) Official ERS/ATS clinical practice guidelines for NIV in ARF suggested NIV to prevent post-extubation respiratory failure in patients at high-risk of extubation failure (Conditional recommendation, low certainty of evidence).(23) Indeed early NIV administration after planned extubation decreases both rate of reintubation and mortality. Compared to NIV, HFNC improves patient comfort and limits the risk of NIV-related adverse events and may be better tolerated alternative to NIV.

Evidence summary

Seven RCTs (16-22) which compared HFNC to NIV in patients at high risk of reintubation were found.(79, 113-118) Two studies reported few outcomes of interest,(114, 117) and one study compared HFNC with CPAP (5 cmH2O through a mechanical valve) and was not included in the comparison.(113) Of the remaining 4 studies two enrolled only patients with Chronic Obstructive Pulmonary Disease (COPD) (115, 118) and one compared NIV interspaced with HFNC between NIV sessions VS. HFNC alone.(116) Compared to NIV, HFNC increases the rate of reintubation (RR 1.31, 95% CI 1.04 to 1.64; RD 4.4%, 95%CI 0.6 to 9.2; high certainty), with little effect on mortality (RR 1.07 95% CI 0.84 to 1.36; RD 1.0%, 95%CI -2.3 to 5.1; moderate certainty). HFNC results in slightly lower length of stay in ICU (MD 1.0 day lower, 95% CI 1.52 to 0.47 days lower; high certainty) and hospital (MD 1.44 days lower, 95% CI 2.63 to 0.25 days lower; high certainty). Compared to NIV, HFNC provides a small increase in patient comfort (SMD 0.73 SD lower, 95% CI 0.98 to 0.49 SD lower, high certainty). There is no difference with respect to respiratory rate (MD 0.59 RPM lower, 95% CI -2.48 to 1.29; high certainty) and gas exchange (PaO₂/FiO₂ MD 3.86, 95%CI 0.39 to 7.34; high certainty; PaCO2 MD 1.01 mmHg lower; 95%CI -1.47 to -0.55 mmHg, high certainty).

Justification

HFNC appears to result in small but likely clinically important increased risk of reintubation (\sim 4%) compared to NIV in non-surgical patients at high risk of extubation failure. On the other hand, compared to NIV, HFNC slightly improves patient comfort. Therefore, in patients who are intolerant or have contraindications to NIV, HFNC may be an alternative to NIV for preventing post-extubation respiratory failure. NIV interspaced with HFNC breaks

between NIV sessions is a strategy which may be effective to further improve oxygenation and reduce post-extubation respiratory failure by gaining the benefits of NIV, with increased comfort from HFNC. (116) The TF judges the large majority of the patients would likely value avoiding reintubation over the increased comfort of HFNC, and, thus, in patients without any contraindications, NIV would generally be preferred. There is limited evidence related to costs for both NIV and HFNC, and these will likely vary between centers.

4.HFNC IN HYPERCAPNIC RESPIRATORY FAILURE

PICO Question 8: Should HFNC or NIV be used in patients with acute hypercapnic respiratory failure?

Recommendation 8: We suggest a trial of NIV prior to use of HFNC in patients with COPD and acute hypercapnic respiratory failure (conditional recommendation, low certainty of evidence).

Background

COPD is the fourth leading cause of chronic morbidity in the world.(119) COPD can result in acute exacerbations, characterized by worsening of respiratory symptoms and hypercapnic acute-on-chronic respiratory failure.(120) While other conditions, such as neuromuscular disease, may be characterized by acute episodes of acute respiratory failure, the mechanism for the increase in carbon dioxide is distinct from COPD.(121) Official ERS/ATS guidelines recommend NIV for patients with COPD and acute hypercapnic acidotic respiratory failure ($pH \le 7.35$), including those requiring endotracheal intubation and mechanical ventilation, unless the patient is immediately deteriorating.(23) HFNC has physiologic rationale (ie. oxygenation, positive pressure, reduced deadspace) for use in hypercapnic exacerbation of COPD, along with its ease of use and patient comfort , make it an alternative to NIV for acute-on-chronic hypercapnic respiratory failure of mild to moderate severity degree of respiratory acidosis.(3, 28, 122) However, its role in COPD and other diseases presenting with acute hypercapnic respiratory failure is not yet well established.

Evidence summary

Five parallel-group RCTs (123-127) and one crossover RCT (128) comparing HFNC to NIV in hypercapnic respiratory failure, of which most patients had COPD, were found. Mean baseline PaCO₂ ranged from 56 to 73.7 mmHg, and pH ranged between 7.26 to 7.4, indicating mild to moderate hypercapnic decompensated respiratory failure. HFNC may not reduce mortality (RR 0.82, 95% CI 0.46 to 1.47; RD -3.1%, 95%CI -9.2 to 8.0, low certainty) or intubation rate (RR 0.79, 95% CI 0.46 to 1.35; RD -3.6%, 95% CI -9.3 to 6.0; low certainty), both limited by very serious imprecision. Length of stay in ICU (MD 0.1, 95% CI -0.73 to 0.94, moderate certainty) and hospital (MD -0.82, 95% CI -1.83 to 0.20) are similar between HFNC and NIV. HFNC may be more comfortable compared to NIV (MD -0.57, 95% CI -0.98 to -0.16, low certainty), although dyspnea is similar (MD -0.31, 95% CI -0.94 to 0.33, moderate certainty). Gas exchange, including PaCO₂, and respiratory rate were similar between HFNC and NIV.

Justification

Overall, the evidence for mortality and intubation is of low certainty, primarily due to imprecision, which does not rule out a clinically significant benefit or harm of HFNC VS. NIV. This is insufficient to make a recommendation in favor of HFNC, given the highcertainty evidence for the use of NIV in COPD, and that more evidence would be required before HFNC could be considered equivalent or superior to NIV.(23) Hence, the panel chose to make a weak/conditional recommendation, suggesting a trial of NIV prior to use of HFNC. While NIV has high evidence for hypercapnic acidotic respiratory failure, it cannot be tolerated by some patients, who may prefer HFNC being more comfortable, and allowing easier communication, feeding, and oral care. A trial of NIV allows clinicians to determine the severity of respiratory failure, the response to treatment, and whether a patient can have a transition to HFNC. HFNC should be preferred over COT during breaks off NIV, but also in exacerbated COPD patients as HFNC significantly reduces the activation of the diaphragm and improves comfort, without affecting gas exchange. (129)

HFNC settings were heterogeneous. The flow was set in a range between 35 and 60 L/min and titrated as much as tolerated by the patients. The temperature was set at 34 or 37°C according to patient's preference, whereas FiO₂ was adjusted to achieve a arterial oxygen saturation with pulse oximetry (SpO₂) between 88% and 92%.

There is poor evidence on resource requirements. The cost of one HFNC device (e.g., interface, circuit, humidity) may be similar to that of a ventilator for NIV, although other resources (e.g., staffing and monitoring), and some ICU ventilators have integrated both HFNC and NIV software, making the interface the only substantive cost difference. In addition, the prescription of HFNC requires fewer resources than NIV, even in terms of healthcare workload. Acceptability and feasibility of HFNC in COPD is likely high, as clinicians are increasingly comfortable with using HFNC.

Discussion

The TF developed eight evidence-based, actionable recommendations, along with implementation considerations to assist patients, clinicians, policy makers, and other healthcare stakeholders to make rational and evidence-based decisions for using HFNC in the acute care setting. The TF identified key areas where further research is necessary to guide practice. (Table 3)

Acknowledgements

Thank you to Kaitryn Campbell for developing and running the database searches, Elaine Ho for her contributions to screening and data abstraction, and Andrea Cortegiani for input and advice.

	Strong recommendation	Weak recommendation
For patients	situation would want the	The majority of individuals in this situation would want the suggested course of action, but many would not.
For clinicians	the recommended course of action. Adherence to this recommendation according to the guideline could be used as a	Different choices are likely to be appropriate for different patients and therapy should be tailored to the individual patient's circumstances. Those circumstances may include the patient or family's values and preferences.

Table 1: Interpretation of strong and conditional recommendations

For	policy-	The recommendation can be	Policy making will require substantial
makers		adapted as policy in most	debates and involvement of many
		situations including for the use	stakeholders. Policies are also more
		as performance indicators.	likely to vary between regions.
			Performance indicators would have to
			focus on the fact that adequate
			deliberation about the management
			options has taken place.

Reproduced from The GRADE Handbook (6)

Table 2: PICO questions and recommendations

Question	Recommendation	
1. Should HFNC or COT be used	The ERS task force suggests the use of HFNC over COT	
in patients with acute	in patients with acute hypoxemic respiratory failure	
hypoxemic respiratory failure?	(conditional recommendation, moderate certainty of	
	evidence).	
2. Should HFNC or NIV be used	The ERS task force suggests the use of HFNC over NIV	
in patients with acute	in acute hypoxemic respiratory failure. (conditional	
hypoxemic respiratory failure?	recommendation, very low certainty of evidence)	
3. Should HFNC or COT be used	The ERS task force suggests the use of HFNC over COT	
during breaks from NIV in	during breaks from NIV in patients with acute	
patients with acute hypoxemic	hypoxemic respiratory failure (conditional	
respiratory failure?	recommendation, low certainty of evidence)	
4. Should HFNC or COT be used	The ERS task force suggests the use of either COT or	
in post-operative patients after	HFNC in postoperative patients at low risk of	
extubation?	respiratory complications. (conditional	
	recommendation, low certainty of evidence)	
5. Should HFNC or NIV be used	The ERS task force suggests the use of either HFNC or	
in post-operative patients after	NIV in postoperative patients at high risk of	
extubation?	respiratory complications. (conditional	
	recommendation, low certainty of evidence).	
6. Should HFNC or COT be used	The ERS task force suggests the use of HFNC over COT	
in non-surgical patients after	in non-surgical patients after extubation (conditional	
extubation?	recommendation, low certainty of evidence).	

Question	Recommendation
7. Should HFNC or NIV be used	The ERS task force suggests the use of NIV over HFNC
in non-surgical patients after	for patients at high risk of extubation failure, unless
extubation?	there are absolute or relative contraindications to NIV
	(conditional recommendation, moderate certainty of
	evidence).
8. Should HFNC or NIV be used	The ERS task force suggests a trial of NIV prior to use
in patients with acute	of HFNC in patients with COPD and acute
hypercapnic respiratory failure?	hypercapnic respiratory failure (conditional
	recommendation, low certainty of evidence).

Table 3: Research recommendations

Question	Key research recommendations
1. Should HFNC or COT be used in patients with acute hypoxemic respiratory failure?	More evidence is needed to identify patients at high risk of deterioration and therefore more likely to benefit from HFNC. Which treatment (HFNC or COT) results in aerosolization of infectious particles in COVID-19, and what are the clinical implications of this?
2. Should HFNC or NIV be used in patients with acute hypoxemic respiratory failure?	More evidence needed to assess the impact of HFNC vs. NIV in COVID-19 and other viral illnesses , as well as in patients at different risk of induced lung injury, different PaO ₂ /FiO ₂ ratio severity. More evidence is needed regarding effectiveness of HFNC vs. NIV in both helmet and facemask forms. Which treatment (HFNC or COT) results in aerosolization of infectious particles in COVID-19, and what are the clinical implications of this?
during breaks from NIV in patients with acute hypoxemic respiratory failure?4. Should HFNC or COT be used	More evidence is needed to identify patients who are likely to benefit from HFNC during breaks from NIV (hypoxic and hypercapnic populations). More evidence is needed to identify which patients (type of surgery, comorbidities, PaO ₂ /FiO ₂ level) are most likely to benefit from HFNC over COT when used post-operatively according to different settings (high vs

Question	Key research recommendations
	low intensity monitoring); however it is likely that any such effects in low-risk groups will be small.
	Further large RTCs are needed to compare NIV and HFNC in different subgroups of surgical patients according to different settings (high vs low intensity monitoring). Additional research is needed to identify the subgroups of post-operative patients at high risk of respiratory failure most likely to benefit from use of combination treatment (NIV plus HFNC) vs. NIV alone.
	More evidence is needed to identify which patients (underlying disease, comorbidities, PaO ₂ /FiO ₂ level) according to different settings (high vs low intensity monitoring) are most likely to benefit from post extubation HFNC over COT.
	More evidence is needed to identify which patients (underlying disease, comorbidities, PaO ₂ /FiO ₂ level) according to different settings (high vs low intensity monitoring) are most likely to benefit from postextubation HFNC over COT are most likely to benefit from NIV over HFNC

Question	Key research recommendations
8. Should HFNC or NIV be used	More randomized data are required to determine
in patients with acute	populations where HFNC can be a first-line alternative
hypercapnic respiratory failure?	to NIV (eg. severity of COPD; patients with
	hypercapnic failure from causes other than COPD;
	hypesecretion, poor mask tolerance, agitation).
	More evidence needed to predict which patients are
	likely to successfully transition to HFNC from NIV.

References

1. Chidekel A, Zhu Y, Wang J, Mosko JJ, Rodriguez E, Shaffer TH. The effects of gas humidification with high-flow nasal cannula on cultured human airway epithelial cells. Pulmonary medicine. 2012;2012.

Renda T, Corrado A, Iskandar G, Pelaia G, Abdalla K, Navalesi P. High-flow nasal oxygen therapy in intensive care and anaesthesia. British journal of anaesthesia.
 2018;120(1):18-27.

3. Pisani L, Astuto M, Prediletto I, Longhini F. High flow through nasal cannula in exacerbated COPD patients: a systematic review. Pulmonology. 2019;25(6):348-54.

4. Ricard J-D, Roca O, Lemiale V, Corley A, Braunlich J, Jones P, et al. Use of nasal high flow oxygen during acute respiratory failure. Intensive care medicine. 2020:1-10.

5. Kang BJ, Koh Y, Lim C-M, Huh JW, Baek S, Han M, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive care medicine. 2015;41(4):623-32.

6. Schunemann H. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2. http://www.cc-ims.net/gradepro. 2008.

7. Covidence. Covidence Systematic Review Software [Computer Software]. 2017.

8. Manager R. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2014.

 Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66(2):158-72.

 Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al.
 GRADE guidelines: 13. Preparing summary of findings tables and evidence profilescontinuous outcomes. J Clin Epidemiol. 2013;66(2):173-83. 11. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6.

12. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407-15.

Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12):1294-302.

14. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol.
2011;64(12):1303-10.

 Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12):1283-93.

 Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64(12):1277-82.

Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines:
 Framing the question and deciding on important outcomes. J Clin Epidemiol.
 2011;64(4):395-400.

Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al.
 GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726-35.

19. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.

20. GRADEpro G. GRADEpro guideline development tool [software]. McMaster University. 2015;435.

21. Matthay MA, Thompson BT, Ware LB. The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included? The Lancet Respiratory Medicine. 2021.

22. Scala R, Heunks L. Highlights in acute respiratory failure. Eur Respiratory Soc; 2018.

23. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. European Respiratory Journal. 2017;50(2).

24. Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. American journal of respiratory and critical care medicine. 2017;195(4):438-42.

25. Yoshida T, Grieco DL, Brochard L, Fujino Y. Patient self-inflicted lung injury and positive end-expiratory pressure for safe spontaneous breathing. Current opinion in critical care. 2020;26(1):59-65.

Papazian L, Corley A, Hess D, Fraser JF, Frat J-P, Guitton C, et al. Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. Intensive care medicine.
 2016;42(9):1336-49.

27. Mauri T, Turrini C, Eronia N, Grasselli G, Volta CA, Bellani G, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2017;195(9):1207-15.

Cortegiani A, Crimi C, Noto A, Helviz Y, Giarratano A, Gregoretti C, et al. Effect of high-flow nasal therapy on dyspnea, comfort, and respiratory rate. Critical Care.
 2019;23(1):1-6.

29. Azoulay E, Pickkers P, Soares M, Perner A, Rello J, Bauer PR, et al. Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Med. 2017;43(12):1808-19.

30. Frat J-P, Coudroy R, Marjanovic N, Thille AW. High-flow nasal oxygen therapy and noninvasive ventilation in the management of acute hypoxemic respiratory failure. Annals of translational medicine. 2017;5(14).

 Parke RL, McGuinness SP, Eccleston ML. A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients. Respir Care.
 2011;56(3):265-70.

32. Bell N, Hutchinson CL, Green TC, Rogan E, Bein KJ, Dinh MM. Randomised control trial of humidified high flow nasal cannulae versus standard oxygen in the emergency department. Emerg Med Australas. 2015;27(6):537-41.

 Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med.
 2015;372(23):2185-96.

34. Lemiale V, Mokart D, Mayaux J, Lambert J, Rabbat A, Demoule A, et al. The effects of a 2-h trial of high-flow oxygen by nasal cannula versus Venturi mask in immunocompromised patients with hypoxemic acute respiratory failure: a multicenter randomized trial. Crit Care. 2015;19:380.

35. Rittayamai N, Tscheikuna J, Praphruetkit N, Kijpinyochai S. Use of High-Flow Nasal Cannula for Acute Dyspnea and Hypoxemia in the Emergency Department. Respir Care. 2015;60(10):1377-82.

36. Jones PG, Kamona S, Doran O, Sawtell F, Wilsher M. Randomized Controlled Trial of Humidified High-Flow Nasal Oxygen for Acute Respiratory Distress in the Emergency Department: The HOT-ER Study. Respir Care. 2016;61(3):291-9.

37. Makdee O, Monsomboon A, Surabenjawong U, Praphruetkit N, Chaisirin W, Chakorn T, et al. High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in Emergency Department Patients With Cardiogenic Pulmonary Edema: A Randomized Controlled Trial. Ann Emerg Med. 2017;70(4):465-72.e2.

38. Azoulay E, Lemiale V, Mokart D, Nseir S, Argaud L, Pene F, et al. Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial. Jama. 2018;320(20):2099-107.

39. Raeisi S, Fakharian A, Ghorbani F, Jamaati HR, Mirenayat MS. Value and Safety of High Flow Oxygenation in the Treatment of Inpatient Asthma: A Randomized, Doubleblind, Pilot Study. Iran. 2019;18(6):615-23.

40. Geng W, Batu W, You S, Tong Z, He H. High-Flow Nasal Cannula: A Promising Oxygen Therapy for Patients with Severe Bronchial Asthma Complicated with Respiratory Failure. Can Respir J. 2020;2020:2301712.

41. Ko DR, Beom J, Lee HS, You JS, Chung HS, Chung SP. Benefits of high-flow nasal cannula therapy for acute pulmonary edema in patients with heart failure in the emergency department: a prospective multi-center randomized controlled trial. Journal of clinical medicine. 2020;9(6):1937.

42. NÖ AM, Temel Ş, YÜksel R, GÜndoĞan K, Eser B, Kaynar L, et al. The Use of High-flow Nasal Oxygen vs. Standard Oxygen Therapy in Hematological Malignancy Paitnets with Acute Respiratory Failure in Hematology Wards. Turkish Journal of Medical Sciences. 2021.
43. Cuquemelle E, Pham T, Louis B, Papon JF, Brochard L. Heated and humidified high flow oxygen therapy reduces discomfort during hypoxemic respiratory failure. Intensive Care Medicine. 2011;37:S190.

44. Schwabbauer N, Berg B, Blumenstock G, Haap M, Hetzel J, Riessen R. Nasal highflow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and noninvasive ventilation (NIV). BMC anesthesiol. 2014;14:66.

45. Ruangsomboon O, Dorongthom T, Chakorn T, Monsomboon A, Praphruetkit N, Limsuwat C, et al. High-Flow Nasal Cannula Versus Conventional Oxygen Therapy in

Relieving Dyspnea in Emergency Palliative Patients With Do-Not-Intubate Status: A Randomized Crossover Study. Ann Emerg Med. 2019;18:18.

46. Bos LD, Artigas A, Constantin J-M, Hagens LA, Heijnen N, Laffey JG, et al. Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. European Respiratory Review. 2021;30(159).

47. Renda T, Scala R, Corrado A, Ambrosino N, Vaghi A. Adult Pulmonary Intensive and Intermediate Care Units: the Italian Thoracic Society (ITS-AIPO) Position Paper.

Respiration. DOI: 10.1159/000516332, in press

48. Jahagirdar D, Picheca L. Heated humidified high flow oxygen for respiratory support: a review of clinical effectiveness, cost-effectiveness, and guidelines. 2019.

49. Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğlu U. Severe covid-19 pneumonia: pathogenesis and clinical management. bmj. 2021;372.

50. Agarwal A, Basmaji J, Muttalib F, Granton D, Chaudhuri D, Chetan D, et al. Highflow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

2020;67(9):1217-48.

51. Ferioli M, Cisternino C, Leo V, Pisani L, Palange P, Nava S. Protecting healthcare workers from SARS-CoV-2 infection: practical indications. European Respiratory Review. 2020;29(155).

52. Franco C, Facciolongo N, Tonelli R, Dongilli R, Vianello A, Pisani L, et al. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. European Respiratory Journal. 2020;56(5).

53. Winck J, Scala R. Non-invasive respiratory support paths in hospitalized patients with COVID-19: Proposal of an algorithm. Pulmonology. 2021.

54. Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study. Crit Care. 2020;24(1):28.

55. Ibarra-Estrada MÁ, Marín-Rosales M, García-Salcido R, Aguirre-Díaz SA, Vargas-Obieta A, Chávez-Peña Q, et al. Prone positioning in non-intubated patients with COVID-19 associated acute respiratory failure, the PRO-CARF trial: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):1-2.

56. Al-Hazzani W. Awake prone position in hypoxemic patients with coronavirus disease 19 (COVI-PRONE): a randomized clinical trial (COVI-PRONE). Clinical Trials gov Accessed January. 2021;6.

57. Garcia MA, Rampon GL, Doros G, Jia S, Jagan N, Gillmeyer K, et al. Rationale and Design of the Awake Prone Position for Early Hypoxemia in COVID-19 (APPEX-19) Study Protocol. Annals of the American Thoracic Society. 2021(ja).

58. Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on non-invasive support. Minerva Anestesiol. 2019;85(9):1014-23.

59. Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE study. American journal of respiratory and critical care medicine. 2017;195(1):67-77.
60. Carteaux G, Millán-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of noninvasive ventilation for de novo acute hypoxemic respiratory failure: role of tidal volume. Critical care medicine. 2016;44(2):282-90.

61. Frat JP, Ragot S, Coudroy R, Constantin JM, Girault C, Prat G, et al. Predictors of Intubation in Patients With Acute Hypoxemic Respiratory Failure Treated With a Noninvasive Oxygenation Strategy. Crit Care Med. 2018;46(2):208-15.

62. Patel BK, Kress JP. The changing landscape of noninvasive ventilation in the intensive care unit. Jama. 2015;314(16):1697-9.

63. Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochwerg B, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. Jama. 2020;324(1):57-67.

64. Azevedo JR, Montenegro WS, Leitao AL, Silva MM, Prazeres JS, Maranhao JP. High flow nasal cannula oxygen (HFNC) versus non-invasive positive pressure ventilation (NIPPV) in acute hypoxemic respiratory failure. A pilot randomized controlled trial. Intensive Care Medicine Experimental. 2015;3(Supplement 1).

65. Doshi P, Whittle JS, Bublewicz M, Kearney J, Ashe T, Graham R, et al. High-Velocity Nasal Insufflation in the Treatment of Respiratory Failure: A Randomized Clinical Trial. Ann Emerg Med. 2018;72(1):73-83.e5.

66. Shebl E, Embarak S. High-flow nasal oxygen therapy versus noninvasive ventilation in chronic interstitial lung disease patients with acute respiratory failure. Egyptian Journal of Chest Diseases and Tuberculosis. 2018;67(3):270-5.

67. Adi O, Kai Fei S, Azma Haryaty A, Mohamed Sakan M. Preliminary report: A randomized controlled trial comparing helmet continuous positive airway pressure (CPAP) vs high flow nasal cannula (HFNC) for treatment of acute cardiogenic pulmonary oedema in the emergency department. Critical Care Conference: 39th International Symposium on Intensive Care and Emergency Medicine Belgium. 2019;23(Supplement 2).

68. Artaud-Macari E, Bubenheim M, Le Bouar G, Carpentier D, Grange S, Boyer D, et al. High-flow oxygen therapy vs non invasive ventilationa prospective cross-over physiological study of alveolar recruitment in acute respiratory failure. Annals of Intensive Care Conference: French Intensive Care Society International Congress Reanimation. 2019;9(Supplement 1).

69. Grieco DL, Menga LS, Raggi V, Bongiovanni F, Anzellotti GM, Tanzarella ES, et al. Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure. Am J Respir Crit Care Med. 2020;201(3):303-12. 70. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. Jama. 2016;315(22):2435-41.

71. Grieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, et al. Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial. JAMA. 2021.

72. Frat JP, Brugiere B, Ragot S, Chatellier D, Veinstein A, Goudet V, et al. Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: an observational pilot study. Respir Care. 2015;60(2):170-8.

73. Spoletini G, Mega C, Pisani L, Alotaibi M, Khoja A, Price LL, et al. High-flow nasal therapy vs standard oxygen during breaks off noninvasive ventilation for acute respiratory failure: A pilot randomized controlled trial. J Crit Care. 2018;48:418-25.

74. Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, et al. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. European Journal of Anaesthesiology EJA. 2015;32(2):88-105.

75. O'Gara B, Talmor D. Perioperative lung protective ventilation. Bmj. 2018;362.

76. Odor PM, Bampoe S, Gilhooly D, Creagh-Brown B, Moonesinghe SR. Perioperative interventions for prevention of postoperative pulmonary complications: systematic review and meta-analysis. bmj. 2020;368.

77. Leone M, Einav S, Chiumello D, Constantin J-M, De Robertis E, De Abreu MG, et al. Noninvasive respiratory support in the hypoxaemic peri-operative/periprocedural patient: a joint ESA/ESICM guideline. Intensive care medicine. 2020:1-17. 78. Stephan F, Barrucand B, Petit P, Rezaiguia-Delclaux S, Medard A, Delannoy B, et al. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. Jama. 2015;313(23):2331-9.

79. Hernandez G, Vaquero C, Colinas L, Cuena R, Gonzalez P, Canabal A, et al. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. Jama. 2016;316(15):1565-74.

80. Yu Y, Qian X, Liu C, Zhu C. Effect of high-flow nasal cannula versus conventional oxygen therapy for patients with thoracoscopic lobectomy after extubation. Canadian respiratory journal. 2017;2017.

81. Xia M, Li W, Yao J, Jin Y, Du G, Xu Q, et al. A postoperative comparison of high-flow nasal cannula therapy and conventional oxygen therapy for esophageal cancer patients. Annals of Palliative Medicine. 2021.

82. D'Cruz RF, Hart N, Kaltsakas G. High-flow therapy: physiological effects and clinical applications. Breathe. 2020;16(4).

83. Parke R, McGuinness S, Dixon R, Jull A. Open-label, phase II study of routine highflow nasal oxygen therapy in cardiac surgical patients. Br J Anaesth. 2013;111(6):925-31.

84. Corley A, Bull T, Spooner AJ, Barnett AG, Fraser JF. Direct extubation onto high-flow nasal cannulae post-cardiac surgery versus standard treatment in patients with a BMI >=30: a randomised controlled trial. Intensive Care Med. 2015;41(5):887-94.

85. Ansari BM, Hogan MP, Collier TJ, Baddeley RA, Scarci M, Coonar AS, et al. A Randomized Controlled Trial of High-Flow Nasal Oxygen (Optiflow) as Part of an Enhanced Recovery Program After Lung Resection Surgery. Ann Thorac Surg. 2016;101(2):459-64.

86. Futier E, Paugam-Burtz C, Godet T, Khoy-Ear L, Rozencwajg S, Delay JM, et al. Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA). Intensive Care Med. 2016;42(12):1888-98. 87. Blaudszun G, Zochios V, Butchart A, Earwaker M, Lawson-Brown W, Jones N, et al. A randomised controlled trial of highflow nasal oxygen (OptiflowTM) in highrisk cardiac surgical patients. Anaesthesia. 2017;72 (Supplement 4):15.

88. Brainard J, Scott BK, Sullivan BL, Fernandez-Bustamante A, Piccoli JR, Gebbink MG, et al. Heated humidified high-flow nasal cannula oxygen after thoracic surgery - A randomized prospective clinical pilot trial. J Crit Care. 2017;40:225-8.

 Sahin M, El H, Akkoc I. Comparison of Mask Oxygen Therapy and High-Flow Oxygen Therapy after Cardiopulmonary Bypass in Obese Patients. Can Respir J. 2018;2018:1039635.

90. Zochios V, Collier T, Blaudszun G, Butchart A, Earwaker M, Jones N, et al. The effect of high-flow nasal oxygen on hospital length of stay in cardiac surgical patients at high risk for respiratory complications: a randomised controlled trial. Anaesthesia. 2018;73(12):1478-88.

91. Ferrando C, Puig J, Serralta F, Carrizo J, Pozo N, Arocas B, et al. High-flow nasal cannula oxygenation reduces postoperative hypoxemia in morbidly obese patients: a randomized controlled trial. Minerva Anestesiol. 2019;85(10):1062-70.

92. Pennisi MA, Bello G, Congedo MT, Montini L, Nachira D, Ferretti GM, et al. Early nasal high-flow versus Venturi mask oxygen therapy after lung resection: a randomized trial. Crit Care. 2019;23(1):68.

93. Twose P, Thomas C, Morgan M, Broad MA. Comparison of high-flow oxygen therapy with standard oxygen therapy for prevention of postoperative pulmonary complications after major head and neck surgery involving insertion of a tracheostomy: a feasibility study. Br J Oral Maxillofac Surg. 2019;57(10):1014-8.

94. Tatsuishi W, Sato T, Kataoka G, Sato A, Asano R, Nakano K. High-Flow Nasal Cannula Therapy With Early Extubation for Subjects Undergoing Off-Pump Coronary Artery Bypass Graft Surgery. Respir Care. 2020;65(2):183-90. 95. Vourc'h M, Nicolet J, Volteau C, Caubert L, Chabbert C, Lepoivre T, et al. High-Flow Therapy by Nasal Cannulae Versus High-Flow Face Mask in Severe Hypoxemia After Cardiac Surgery: A Single-Center Randomized Controlled Study-The HEART FLOW Study. J Cardiothorac Vasc Anesth. 2020;34(1):157-65.

96. Stephan F, Berard L, Rezaiguia-Delclaux S, Amaru P, Bi POPSG. High-Flow Nasal Cannula Therapy Versus Intermittent Noninvasive Ventilation in Obese Subjects After Cardiothoracic Surgery. Respir Care. 2017;62(9):1193-202.

97. Esteban A, Frutos-Vivar F, Muriel A, Ferguson ND, Peñuelas O, Abraira V, et al. Evolution of mortality over time in patients receiving mechanical ventilation. American journal of respiratory and critical care medicine. 2013;188(2):220-30.

98. Miu T, Joffe AM, Yanez ND, Khandelwal N, Dagal AH, Deem S, et al. Predictors of reintubation in critically ill patients. Respiratory care. 2014;59(2):178-85.

99. Tiruvoipati R, Lewis D, Haji K, Botha J. High-flow nasal oxygen vs high-flow face mask: a randomized crossover trial in extubated patients. J Crit Care. 2010;25(3):463-8.

100. Maggiore SM, Idone FA, Vaschetto R, Festa R, Cataldo A, Antonicelli F, et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med. 2014;190(3):282-8.

101. Perbet S, Gerst A, Chabanne R, Soummer A, Faure JS, Pascal J, et al. High-flow nasal oxygen cannula versus conventional oxygen therapy to prevent postextubation lung aeration loss: A multicentric randomized control lung ultrasound study. Intensive Care Medicine. 2014;40(1):S128.

102. Rittayamai N, Tscheikuna J, Rujiwit P. High-flow nasal cannula versus conventional oxygen therapy after endotracheal extubation: a randomized crossover physiologic study. Respir Care. 2014;59(4):485-90.

103. Hernandez G, Vaquero C, Gonzalez P, Subira C, Frutos-Vivar F, Rialp G, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on

Reintubation in Low-Risk Patients: A Randomized Clinical Trial. Jama. 2016;315(13):1354-61.

104. Arman PD, Varn MN, Povian S, Davis A, Uchakin P, Bhar A, et al. Effects of direct extubation to high-flow nasal cannula compared to standard nasal cannula in patients in the intensive care unit. American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference, ATS. 2017;195(no pagination).

105. Fernandez R, Subira C, Frutos-Vivar F, Rialp G, Laborda C, Masclans JR, et al. High-flow nasal cannula to prevent postextubation respiratory failure in high-risk non-hypercapnic patients: a randomized multicenter trial. Ann Intensive Care. 2017;7(1):47.
106. Song HZ, Gu JX, Xiu HQ, Cui W, Zhang GS. The value of high-flow nasal cannula oxygen therapy after extubation in patients with acute respiratory failure. Clinics.

2017;72(9):562-7.

107. Di Mussi R, Spadaro S, Stripoli T, Volta CA, Trerotoli P, Pierucci P, et al. High-flow nasal cannula oxygen therapy decreases postextubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease. Crit Care. 2018;22(1):180.
108. Cho JY, Kim H-S, Kang H, Kim S-H, Choe KH, Lee KM, et al. Comparison of Postextubation Outcomes Associated with High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients at High Risk of Reintubation: a Randomized Clinical Trial. Journal of Korean medical science. 2020;35(25).

109. Hu TY, Lee CH, Cheng KH, Tan MC, Hua HF, Kuo LK. Effect of high-flow nasal oxygen vs. Conventional oxygen therapy on extubation outcomes and physiologic changes for patients with high risk of extubation failure in the medical ICU: A tertiary center, randomized, controlled trial. International Journal of Gerontology. 2020;14(1):36-41.

110. Matsuda W, Hagiwara A, Uemura T, Sato T, Kobayashi K, Sasaki R, et al. High-Flow Nasal Cannula May Not Reduce the Re-Intubation Rate after Extubation in Respiratory Failure Compared With a Large-Volume Nebulization-Based Humidifier. Respir Care. 2020;28:28. 111. Eaton Turner E, Jenks M. Cost-effectiveness analysis of the use of high-flow oxygen through nasal cannula in intensive care units in NHS England. Expert rev. 2018;18(3):331-7.
112. Maggiore SM, Battilana M, Serano L, Petrini F. Ventilatory support after extubation in critically ill patients. The Lancet Respiratory Medicine. 2018;6(12):948-62.

113. Theerawit P, Natpobsuk N, Sutherasan Y. The efficacy of the Whispherflow CPAP system versus high flow nasal cannula in patients at high risk for postextubation failure. Intensive Care Medicine Experimental Conference: 30th Annual Congress of the European Society of Intensive Care Medicine, ESICM. 2017;5(2 Supplement 1).

114. Zhang JC, Wu FX, Meng LL, Zeng CY, Lu YQ. [A study on the effects and safety of sequential humidified high flow nasal cannula oxygenation therapy on the COPD patients after extubation]. Chung Hua I Hsueh Tsa Chih. 2018;98(2):109-12.

115. Jing G, Li J, Hao D, Wang T, Sun Y, Tian H, et al. Comparison of high flow nasal cannula with noninvasive ventilation in chronic obstructive pulmonary disease patients with hypercapnia in preventing postextubation respiratory failure: A pilot randomized controlled trial. Res Nurs Health. 2019;42(3):217-25.

116. Thille AW, Muller G, Gacouin A, Coudroy R, Decavele M, Sonneville R, et al. Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial. Jama. 2019;322(15):1465-75.

117. Tseng CW, Chao KY, Chiang CE, Liu WL, Chou WR, Wu HL, et al. The efficacy of heated humidifier high-flow nasal cannula compared with noninvasive positive-pressure ventilation in prevention of reintubation in patients with prolonged mechanical ventilation. European Respiratory Journal Conference: 29th International Congress of the European Respiratory Society, ERS Spain. 2019;54(Supplement 63).

118. Tan D, Walline JH, Ling B, Xu Y, Sun J, Wang B, et al. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease

patients after extubation: a multicenter, randomized controlled trial. Critical Care. 2020;24(1):1-10.

Halbert R, Natoli J, Gano A, Badamgarav E, Buist AS, Mannino D. Global burden of
COPD: systematic review and meta-analysis. European Respiratory Journal. 2006;28(3):52332.

120. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. American journal of respiratory and critical care medicine. 2017;195(5):557-82.

121. Deenen JC, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. Journal of neuromuscular diseases. 2015;2(1):73-85.

122. Bruni A, Garofalo E, Cammarota G, Murabito P, Astuto M, Navalesi P, et al. High Flow Through Nasal Cannula in Stable and Exacerbated Chronic Obstructive Pulmonary Disease Patients. Rev Recent Clin Trials. 2019;14(4):247-60.

123. Papachatzakis I, Velentza L, Kontogiannis S, Trakada G. High flow nasal cannula with warm humidified air versus non-invasive mechanical ventilation in respiratory failure type II. European Respiratory Journal Conference: European Respiratory Society International Congress, ERS. 2017;50(Supplement 61).

124. Cong L, Zhou L, Liu H, Wang J. Original article outcomes of high-flow nasal cannula versunon-invasive positive pressure ventilation for patients with acute exacerbations of chronic obstructive pulmonary disease. International Journal of Clinical and Experimental Medicine. 2019;12(8):10863-7.

125. Wang JJ JH, Li Q. Randomized controlled study of HFNC and NPPV in the treatment of AECOPD combined with type II respiratory failure. Chinese Journal of integrative Medicine. 2019:1-15. 126. Cortegiani A, Longhini F, Madotto F, Groff P, Scala R, Crimi C, et al. High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized trial. Critical Care. 2020;24(1):1-13.

127. Doshi PB, Whittle JS, Dungan G, 2nd, Volakis LI, Bublewicz M, Kearney J, et al. The ventilatory effect of high velocity nasal insufflation compared to non-invasive positive-pressure ventilation in the treatment of hypercapneic respiratory failure: A subgroup analysis. Heart Lung. 2020;06:06.

128. Sklar MC, Dres M, Ritayamai N, West B, Pham T, Grieco DL, et al. A randomized cross-over physiological study of high flow nasal oxygen cannula versus non-invasive ventilation in adult patients with cystic fibrosis: The HIFEN study. Intensive Care Medicine Experimental Conference: 30th Annual Congress of the European Society of Intensive Care Medicine, ESICM. 2017;5(2 Supplement 1).

129. Longhini F, Pisani L, Lungu R, Comellini V, Bruni A, Garofalo E, et al. High-Flow Oxygen Therapy After Noninvasive Ventilation Interruption in Patients Recovering From Hypercapnic Acute Respiratory Failure: A Physiological Crossover Trial. Crit Care Med. 2019;47(6):e506-e11.

Supplement: Evidence profiles

ERS Guidelines: High flow nasal cannula in acute respiratory failure

Authors

Simon Oczkowski^{1,2,*} Begüm Ergan^{3,*} Lieuwe Bos^{4,5}, Michelle Chatwin⁶, Miguel Ferrer⁷, Caesare Gregoretti⁸, Leo Heunks⁹, Jean-Pierre Frat ^{10,11}, Federico

Longhini¹², Stefano Nava¹³, Paolo Navalesi¹⁴, Aylin Ozsancak Uğurlu¹⁵, Lara Pisani¹⁶, Teresa Renda¹⁷, Arnaud Thille¹⁸, João Carlos Winck¹⁹, Wolfram Windisch²⁰,

Thomy Tonia²¹, Jeanette Boyd²² Giovanni Sotigu ²³, Raffaele Scala²⁴

*co-first authors

Affiliations

- 1. Department of Medicine, Division of Critical Care, McMaster University, Hamilton, Ontario, Canada
- 2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
- 3. Department of Pulmonary and Critical Care, Dokuz Eylul University School of Medicine, Izmir, Turkey
- 4. Dept of Intensive Care and Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Academic Medical Center, Amsterdam
- 5. Respiratory Medicine, Academic Medical Center, Amsterdam, The Netherlands.
- 6. Academic and Clinical Department of Sleep and Breathing and NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, Sydney Street, London, UK.
- 7. Dept of Pneumology, Respiratory Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBERES, Barcelona, Spain.
- 8. Department of Surgical, Oncological and Oral Science, Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.
- 9. Department of Intensive Care Medicine, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
- 10. Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
- 11. INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.
- 12. Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy
- 13. Dept of Specialistic, Diagnostic and Experimental Medicine, Respiratory and Critical Care, Sant'Orsola Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy
- 14. Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy.
- 15. Department of Pulmonary Medicine, Baskent University, Istanbul, Turkey.
- 16. Respiratory and Critical Care Unit, Alma Mater Studiorum, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy.
- 17. Cardiothoracic and Vascular Department, Respiratory and Critical Care Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.
- 18. Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
- 19. Faculdade de Medicina da Universidade do Porto, Portugal.
- 20. Cologne Merheim Hospital, Dept of Pneumology, Kliniken der Stadt Köln, gGmbH, Witten/Herdecke University, Faculty of Health/School of Medicine, Köln, Germany.
- 21. Institute of Social and Preventive Medicine, University of Bern, Switzterland
- 22. European Lung Foundation (ELF), Sheffield, United Kingdom
- 23. Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical, Experimental Sciences, University of Sassari, Sassari, Italy.
- 24. Pulmonology and Respiratory Intensive Care Unit, S Donato Hospital, Arezzo, Italy.

		Certa	Certainty assessment № of patients Effect								
Nº of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	HFNC	сот	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
Mortality	(90 day)				•	•	•			•	•
4 RCTs	not serious	not serious	not serious	serious ^a	none	208/659 (31.6%)	208/620 (33.5%)	RR 0.97 (0.83 to 1.13)	10 fewer per 1,000 (from 57 fewer to 44 more)	⊕⊕⊕○ MODERATE	CRITICAL
Mortality	(ICU, hosp	oital, or 28 day)	1	<u></u>		1	1	I			
6 RCTs	not serious	not serious	not serious	serious ^a	none	189/773 (24.5%)	187/734 (25.5%)	RR 0.99 (0.84 to 1.17)	3 fewer per 1,000 (from 41 fewer to 43 more)	⊕⊕⊕⊖ MODERATE	CRITICAL
Intubatio	n		!		1						!
11 RCTs	not serious	not serious	not serious	serious ^a	none	231/943 (24.5%)	253/907 (27.9%)	RR 0.89 (0.77 to 1.02)	31 fewer per 1,000 (from 64 fewer to 6 more)	⊕⊕⊕⊖ MODERATE	CRITICAL
Escalatio	n to NIV		!		1	1					!
6 RCTs	not serious	not serious	not serious	serious ^a	none	38/409 (9.3%)	47/388 (12.1%)	RR 0.76 (0.43 to 1.34)	29 fewer per 1,000 (from 69 fewer to 41 more)	⊕⊕⊕○ MODERATE	CRITICAL
Hospital I	ength of s	tay									
5 RCTs	not serious	not serious	not serious	serious ^a	none	683	660	-	MD 0.72 days lower (1.54 lower to 0.1 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
ICU lengt	h of stay		1		1	1	1	I			1
2 RCTs	not serious	not serious	not serious	serious ^b	none	494	482	-	MD 1.97 days higher (1.02 higher to 2.93 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
Patient co	omfort										
6 RCTs	not serious	not serious	not serious	not serious	none	303	293	-	SMD 0.54 lower (0.86 lower to 0.23 lower)		IMPORTANT
Dyspnea											

6 RCTs	not serious	not serious	not serious ^c	serious ^a	none	173	189	-	SMD 0.32 lower (0.66 lower to 0.03 higher)		IMPORTANT
										WODERATE	
PaO2/FiO	2										
4 RCTs	not	serious d	not serious	serious ^a	none	526	514	-	MD 25.01 higher	$\oplus \oplus \bigcirc \bigcirc$	IMPORTANT
	serious								(14.21 lower to 64.24 higher)	LOW	
PaO2			1	!	1	1			1	1	
6 RCTs	not serious	not serious	not serious	not serious	none	202	193	-	MD 16.72 higher (5.74 higher to 27.71 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
PCO2			<u> </u>	1	1	1		<u> </u>			<u> </u>
6 RCTs	not serious	not serious	not serious	not serious	none	202	193	-	MD 0.01 higher (1.17 lower to 1.2 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
Respirato	ory rate			1						1	1
10 RCTs	not serious	not serious	not serious	not serious	none	713	716	-	MD 2.25 lower (3.24 lower to 1.25 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT

CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference

Explanations

a. Significant imprecision which does not rule out clinically significant benefit nor harm.

b. Though Azoulay 2018 demonstrates statistically significant increase in ICU length of stay, when estimated means and SD are used, they are not statistically significant when median (IQR) are compared.

c. Most studies used the validated Borg dyspnea scale.

d. Very significant heterogeneity between the Frat 2015 RCT and the other trials (I2= 93%) of likely clinical significance.

1. Mortality (90 day)

	HFN	с	CO	г		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M–H, Fixed, 95% Cl	Year	r M–H, Fixed, 95% Cl
1.1.1 Immunocompe	etent							
Frat 2015	9	80	14	64	7.4%	0.51 [0.24, 1.11]	2015	5
Jones 2016 Subtotal (95% CI)	35	165 245	24	138 202	12.4% 19.7%	1.22 [0.76, 1.95] 0.96 [0.65, 1.42]	2016	
Total events	44		38					-
Heterogeneity: $Chi^2 =$	3.53. df	= 1 (P)	= 0.06);	$l^2 = 72$	%			
Test for overall effect	,							
1.1.2 Immunocompr	omised							
Frat 2017	4	26	8	30	3.5%	0.58 [0.20, 1.70]	2017	7
Azoulay 2018 Subtotal (95% CI)	160	388 414	162	388 418	76.7% 80.3%	. , .	2018	3
Total events	164		170					
Heterogeneity: $Chi^2 =$	0.94. df	= 1 (P)	= 0.33):	$l^2 = 0\%$	6			
Test for overall effect	,	,						
Total (95% CI)		659		620	100.0%	0.97 [0.83, 1.13]		•
Total events Heterogeneity: Chi ² = Test for overall effect:	,			l ² = 33	8%			0.2 0.5 1 2 5 Favours HFNC Favours COT
Test for subaroup dif	ferences:	Chi ² =	0.00. df	= 1 (P	= 0.95).	$l^2 = 0\%$		

2. Mortality (early - ICU, hospital, or 28 day)

	HFN	С	CO	Г		Risk Ratio			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year		M-H, Random, 95% Cl
1.3.1 Immunocompt	ent								
Frat 2015	8	80	12	64	3.9%	0.53 [0.23, 1.23]	2015		+
Jones 2016	15	165	11	138	4.9%	1.14 [0.54, 2.40]	2016		_ _
Makdee 2017 Subtotal (95% CI)	1	63 308	0	65 267	0.3% 9.1%		2017		· · · · · · · · · · · · · · · · · · ·
Total events	24		23						
Heterogeneity: $Tau^2 =$	= 0.07; Cł	1i ² = 2.	44, df =	2 (P =	0.29); I ²	= 18%			
Test for overall effect	Z = 0.50	(P = 0)).62)						
1.3.2 Immunocompr	omised								
Frat 2017	4	26	6	30	2.1%	0.77 [0.24, 2.43]	2017		
Azoulay 2018	138	388	140	388	76.8%	0.99 [0.82, 1.19]	2018		
Mendil 2019 Subtotal (95% CI)	23	51 465	18	49 467	12.0% 90.9%		2019		 ◆
Total events	165		164						
Heterogeneity: Tau ² =	,		,	2 (P =	0.63); I ²	= 0%			
Test for overall effect	Z = 0.10	(P = 0)).92)						
Total (95% CI)		773		734	100.0%	0.99 [0.84, 1.17]			•
Total events	189		187						
Heterogeneity: Tau ² =	= 0.00; Cł	1i ² = 3.	73, df =	5 ($P =$	0.59); I ²	= 0%		0.02	0.1 1 10 5
Test for overall effect	Z = 0.08	B (P = 0)).93)					0.02	Favours HFNC Favours COT
Test for subgroup dif	ferences:	Chi ² =	0.26, df	= 1 (P	= 0.61),	$I^2 = 0\%$			

3. Intubation

	HFN	с	co	г		Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI		
1.4.1 Immunocompe	tent									
Frat 2015	32	80	31	64	14.4%	0.83 [0.57, 1.19]	2015			
Bell 2015	0	48	1	52	0.2%	0.36 [0.02, 8.64]	2015	· · · · · · · · · · · · · · · · · · ·		
Rittayamai 2015	0	20	0	20		Not estimable	2015			
Jones 2016	9	165	16	138	3.2%	0.47 [0.21, 1.03]	2016			
Makdee 2017	1	63	0	65	0.2%	3.09 [0.13, 74.55]	2017			
Ko 2020	1	34	1	33	0.3%	0.97 [0.06, 14.88]	2020			
Geng 2020	1	16	1	20	0.3%	1.25 [0.08, 18.46]	2020			
Subtotal (95% CI)		426		392	18.5%	0.76 [0.55, 1.05]		•		
Total events	44		50							
1.4.2 Immunocompre Lemaile 2015 Frat 2017 Azoulay 2018 Mendil 2019 Subtotal (95% CI)	omised 4 8 150 24	52 26 388 51 517	2 13 170 16	48 30 388 49 515	0.7% 3.9% 68.9% 7.9% 81.5%	1.85 [0.35, 9.63] 0.71 [0.35, 1.44] 0.88 [0.75, 1.04] 1.44 [0.88, 2.37] 0.99 [0.73, 1.35]	2017 2018			
Total events Heterogeneity: Tau ² = Test for overall effect:				3 (P =	0.21); I ²	= 35%				
Total (95% CI)		943		907	100.0%	0.89 [0.77, 1.02]		•		
Total events Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diff	Z = 1.64	4 (P = 0	.10)					0.02 0.1 1 10 50 Favours HFNC Favours COT		

4. Escalation to NIV

	HFN	с	co	г		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
1.5.1 Immunocompe	tent							
Parke 2011	3	30	12	30	16.6%	0.25 [0.08, 0.80]	2011	
Bell 2015	2	48	2	58	7.5%	1.21 [0.18, 8.26]	2015	
Jones 2016	5	165	7	138	17.3%	0.60 [0.19, 1.84]	2016	
Makdee 2017 Subtotal (95% CI)	1	63 306	3	65 291	5.8% 47.2%		2017	
Total events	11		24					
Heterogeneity: Tau ² =	0.00; Cl	ni ² = 2.	30, df =	3 (P =	0.51); I ²	= 0%		
Test for overall effect:	Z = 2.22	P = 0).03)					
1.5.2 Immunocompre								
Lemaile 2015	6	52	3	48				
Mendil 2019 Subtotal (95% CI)	21	51 103	20	49 97	39.1% 52.8%		2019	
Total events	27		23					
Heterogeneity: Tau ² = Test for overall effect:	,		,	1 (P =	0.39); I ²	= 0%		
rest for overall effect.	2 = 0.5	- (i – (,,,,,					
Total (95% CI)		409		388	100.0%	0.76 [0.43, 1.34]		
Total events	38		47					
Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diff	Z = 0.96	5 (P = 0)).34)					0.05 0.2 1 5 20 Favours HFNC Favours COT

5. Hospital length of stay

	1	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.7.1 Immunocompe	tent									
Jones 2016	5	4.1	165	5.6	4.8	138	46.3%	-0.60 [-1.62, 0.42]	2016	
Makdee 2017	1.1	6.9	63	1.2	4.32	65	15.2%	-0.10 [-2.10, 1.90]	2017	-+-
Geng 2020 Subtotal (95% CI)	6.54	1.85	16 244	7.02	2.32	20 223		,	2020	
Heterogeneity: $Tau^2 =$	0.00; 0	Chi ² =	0.19, d	f = 2 (F	P = 0.9	$(91); I^2 =$	• 0%			
Test for overall effect:	Z = 1.2	28 (P =	• 0.20)			.,				
1.7.2 Immunocompr	omised									
Azoulay 2018	24	19.2	388	27	20	388	8.4%	-3.00 [-5.76, -0.24]	2018	
Mendil 2019	28	30.8	51	36	31.8	49	0.4%	-8.00 [-20.28, 4.28]	2019	
Subtotal (95% CI)			439			437	8.8%	-3.24 [-5.93, -0.55]		\bullet
Heterogeneity: Tau ² =	• 0.00; (Chi² =	0.61, d	f = 1 (F)	P = 0.4	14); I ² =	• 0%			
Test for overall effect:	Z = 2.3	86 (P =	= 0.02)							
Total (95% CI)			683			660	100.0%	-0.72 [-1.54, 0.10]		◆
Heterogeneity: $Tau^2 =$	0.11; 0	Chi ² =	4.51, d	f = 4 (F)	P = 0.3	$(34); I^2 =$: 11%			
Test for overall effect:	,		,							-20 -10 0 10 20
Test for subgroup diff		· _	,	df = 1	(P = 0)).05), l ²	= 73.1%			Favours HFNC Favours COT

6. ICU length of stay

		HFNC			сот			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.6.1 Immunocompt	ent								
Frat 2015 Subtotal (95% CI)	10.7	15.8	106 106	9.1	11.7	94 94		1.60 [-2.23, 5.43] 1.60 [-2.23, 5.43]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 0.8	32 (P =	0.41)						
1.6.2 Immunocompr	omised								
Azoulay 2018 Subtotal (95% CI)	8	7.4	388 388	6	6.67	388 388	93.7% 93.7%	2.00 [1.01, 2.99] 2.00 [1.01, 2.99]	
Heterogeneity: Not ap	plicable								
Test for overall effect:	Z = 3.9	95 (P <	0.000	1)					
Total (95% CI)			494			482	100.0%	1.97 [1.02, 2.93]	
Heterogeneity: $Chi^2 =$	0.04, d	f = 1 (P = 0.8	$(34); I^2 =$	0%			-	
Test for overall effect:									-4 -2 0 2 4 Favours HFNC Favours COT
Test for subgroup diff	ferences	: Chi ² =	= 0.04,	df = 1	(P = 0).84), I ²	= 0%		Favours firme Favours COT

7. Patient comfort (various rating systems)

	н	IFNC			сот			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.8.1 Immunocompe	tent									
Schabbauer 2014	2.7	1.8	14	3.1	2.8	14	10.7%	-0.16 [-0.91, 0.58]	2014	
Frat 2015	29	26	106	40	29	94	21.4%	-0.40 [-0.68, -0.12]	2015	
Bell 2015	3	1.5	48	4	0.74	52	18.0%	-0.85 [-1.26, -0.44]	2015	
Rittayamai 2015	1.6	1.7	20	3.7	2.4	20	12.2%	-0.99 [-1.65, -0.33]	2015	_
Makdee 2017 Subtotal (95% CI)	-8.1	2	63 251	-6.4	1.9	65 245	19.2% 81.5%	-0.87 [-1.23, -0.50] -0.66 [-0.94, -0.39]	2017	•
Test for overall effect: 1.8.2 Immunocompresent			< 0.00	001)						
Lemaile 2015 Subtotal (95% CI) Heterogeneity: Not ap	3	3	52 52	3	3.7	48 48	18.5% 18.5%	0.00 [-0.39, 0.39] 0.00 [-0.39, 0.39]	2015	•
Test for overall effect:	Z = 0.0	00 (P	= 1.00)						
Total (95% CI)			303			293	100.0%	-0.54 [-0.86, -0.23]		•
Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diff	Z = 3.3	85 (P	= 0.00	08)					-	-2 -1 0 1 2 Favours HFNC Favours COT

8. Dyspnea (various measures, Borg Dyspnea Scale or visual analog scale)

	1	HFNC			сот			Std. Mean Difference	Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI	
1.9.1 Immunocompet	ent										
Schabbauer 2014	2.9	2.1	14	3.3	2.3	14	13.3%	-0.18 [-0.92, 0.57]	2014		
Rittayamai 2015	2	1.8	2	3.8	2.3	20	4.7%	-0.76 [-2.23, 0.71]	2015		
Makdee 2017	3.1	2	63	3.6	2.2	65	25.8%	-0.24 [-0.58, 0.11]	2017		
Ruangsomboon 2019	3.3	2	22	5.6	1.8	22	15.7%	-1.19 [-1.83, -0.54]	2019		
Raeisi 2019	6	1.04	20	6.07	0.88	20	16.4%	-0.07 [-0.69, 0.55]	2019		
Subtotal (95% CI)			121			141	75.9%	-0.42 [-0.84, -0.01]		\bullet	
1.9.2 Immunocompro		3	52	3	37	48	24 1%	0 00 [-0 39 0 39]	2015		
Lemaile 2015	3	3	52	3	3.7	48	24.1%	0.00 [-0.39, 0.39]	2015	_ _	
Subtotal (95% CI)			52			48	24.1%	0.00 [-0.39, 0.39]		•	
Heterogeneity: Not app	licable										
Test for overall effect:	Z = 0.00) (P =	1.00)								
Total (95% CI)			173			189	100.0%	-0.32 [-0.66, 0.03]		•	
Heterogeneity: $Tau^2 =$	0.09; Ch	$ni^2 = 1$	0.47, d	f = 5 (F)	P = 0.0)6); I ² =	52%				
Test for overall effect:	Z = 1.81	(P =	0.07)							Favours HFNC Favours COT	
Test for subgroup diffe	rences:	Chi ² =	2.11, 0	df = 1 (P = 0.	15), l ² =	= 52.6%				

9. PaO2:FiO2

	н	FNC			сот			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.10.1 Immunocomp	oetent								
Frat 2015	-130	60	106	-161	77	94	26.6%	31.00 [11.69, 50.31]	_ _
Mauri 2016	-184	53	15	-130	35	15	23.9%	-54.00 [-86.14, -21.86]	_
Mauri 2017 Subtotal (95% CI)	-205	61	17 138	-151	60	17 126		-54.00 [-94.67, -13.33] -24.15 [-88.18, 39.88]	
Heterogeneity: $Tau^2 =$	= 2941.8	6; Chi	$^{2} = 27$	51, df =	= 2 (P	< 0.00	001); I ² =	= 93%	
Test for overall effect:	Z = 0.74	4 (P =	0.46)						
1.10.2 Immunocomp	oromised								
Azoulay 2018 Subtotal (95% CI)	-150	93.3	388 388	-119	58.5	388 388		-31.00 [-41.96, -20.04] -31.00 [-41.96, -20.04]	•
Heterogeneity: Not ap Test for overall effect:	•	4 (P <	0.000	01)					
Total (95% CI)			526			514	100.0%	-25.01 [-64.24, 14.21]	
Heterogeneity: Tau ² =	= 1409.7	5; Chi	$^{2} = 37$.64, df =	= 3 (P	< 0.00	001); I ² =	= 92%	-100 -50 0 50 100
Test for overall effect:	Z = 1.25	5 (P =	0.21)						-100 -50 0 50 100 Favours HFNC Favours COT
Test for subaroup diff	ferences:	Chi ² =	= 0.04.	df = 1	(P = 0)	.84). I ²	= 0%		ravours firme ravours cor

10. PaO2

	н	FNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Mauri 2017	-97.4	23	17	-70	9.6	17	17.9%	-27.40 [-39.25, -15.55]		_ - _
Schabbauer 2014	-101	34	14	-85	22	14	12.3%	-16.00 [-37.21, 5.21]	2014	
Frat 2015	-90	35	106	-93	36	94	19.1%	3.00 [-6.87, 12.87]	2015	
Mauri 2016	-98	39	15	-72	5.2	15	13.0%	-26.00 [-45.91, -6.09]	2016	
Geng 2020	-94.73	4.43	16	-86.98	6.42	20	22.1%	-7.75 [-11.30, -4.20]	2020	-
Ko 2020	-107.47	44.15	34	-73.25	13.02	33	15.6%	-34.22 [-49.71, -18.73]	2020	
Total (95% CI)			202			193	100.0%	-16.72 [-27.71, -5.74]		•
Heterogeneity: Tau ² =	= 138.87; 0	$2hi^2 = 2a$	8.63, d	f = 5 (P -	< 0.000	1); I ² =	83%			
Test for overall effect	:: Z = 2.98 (P = 0.0	03)							Favours HFNC Favours COT

11. PCO2 (most commonly PaCO2)

	H	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Mauri 2017	38.3	5.4	17	38.2	5	17	11.5%	0.10 [-3.40, 3.60]		
Schabbauer 2014	37	5	14	37	6	14	8.4%	0.00 [-4.09, 4.09]	2014	
Frat 2015	35	7	106	35	6	94	43.2%	0.00 [-1.80, 1.80]	2015	_
Mauri 2016	41.1	5.9	15	40.7	5.7	15	8.1%	0.40 [-3.75, 4.55]	2016	
Ko 2020	31.54	8.14	34	32.3	6.22	33	11.7%	-0.76 [-4.22, 2.70]	2020	
Geng 2020	40.22	4.37	16	39.87	4.35	20	17.1%	0.35 [-2.52, 3.22]	2020	
Total (95% CI)			202			193	100.0%	0.01 [-1.17, 1.20]		•
Heterogeneity: Tau ² =	= 0.00; C	$Chi^2 = 0$	0.28, d	f = 5 (P	= 1.00	D); $I^2 =$	0%		_	
Test for overall effect	Z = 0.0	2 (P =	0.98)							Favours HFNC Favours COT

12. Respiratory rate

	H	IFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.13.1 Immunocompe	tent									
Mauri 2017	18	7	17	24	8	17	3.4%	-6.00 [-11.05, -0.95]		
Schabbauer 2014	26	7	14	28	8	14	2.9%	-2.00 [-7.57, 3.57]	2014	
Frat 2015	27	7	106	29	8	94	12.9%	-2.00 [-4.10, 0.10]	2015	
Rittayamai 2015	26	6.2	2	27.5	4.9	20	1.2%	-1.50 [-10.36, 7.36]	2015	
Mauri 2016	22	5.2	15	24	5.2	15	5.8%	-2.00 [-5.72, 1.72]	2016	
Makdee 2017	23.5	3.6	63	26.5	3.9	65	19.8%	-3.00 [-4.30, -1.70]	2017	
Ruangsomboon 2019	26	3.7	22	31.9	9.3	22	4.8%	-5.90 [-10.08, -1.72]	2019	
Ko 2020	21.32	3.32	34	24.3	3.55	33	16.5%	-2.98 [-4.63, -1.33]	2020	
Subtotal (95% CI)			273			280	67.2%	-2.95 [-3.79, -2.10]		◆
Heterogeneity: $Tau^2 = 0$	0.00; Chi	$^{2} = 4.$	57, df =	= 7 (P =	= 0.71); $I^2 = C$	%			
Test for overall effect: Z	2 = 6.84	(P < 0	0.00001	L)						
1.13.2 Immunocompre	omised									
Lemaile 2015	25	5.2	52	25	7.4	48	10.2%	0.00 [-2.53, 2.53]	2015	
Azoulay 2018	25	7.4	388	26	7.4	388	22.5%	-1.00 [-2.04, 0.04]	2018	
Subtotal (95% CI)			440			436	32.8%	-0.85 [-1.82, 0.11]		\bullet
Heterogeneity: $Tau^2 = 0$	0.00: Chi	$^{2} = 0.$	51. df =	= 1 (P =	= 0.47): $ ^2 = 0$	%			
Test for overall effect: Z	,		,							
Total (95% CI)			713			716	100.0%	-2.25 [-3.24, -1.25]		•
Heterogeneity: $Tau^2 = 0$	0.86: Chi	$^{2} = 15$	5.33. df	= 9 (P)	= 0.0	8): $I^2 =$	41%			
Test for overall effect: Z						-,, .				
Test for subgroup diffe					$(\mathbf{P} = 0)$	001)	$^{2} - 00.2\%$	<u>(</u>		Favours HFNC Favours COT

		Certa	iinty assessmer	ıt		Nº of p	atients		Effect		
№ of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	HFNC	NIV	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
Mortality	(90 day)										
1 RCT	not serious	not serious	serious ^a	serious ^b	none	13/106 (12.3%)	31/110 (28.2%)	RR 0.43 (0.24 to 0.78)	161 fewer per 1,000 (from 214 fewer to 62 fewer)		CRITICAL
Mortality	/ (ICU, hos	pital or 28 day)			1						1
3 RCTs	not serious	serious ^c	serious ^a	serious ^d	none	35/234 (15.0%)	47/240 (19.6%)	RR 0.77 (0.52 to 1.14)	45 fewer per 1,000 (from 94 fewer to 27 more)	⊕⊖⊖⊖ VERY LOW	CRITICAL
Intubatio	on	1									1
5 RCTs	not serious	not serious	serious ^a	serious ^d	none	74/352 (21.0%)	92/356 (25.8%)	RR 0.84 (0.61 to 1.16)	41 fewer per 1,000 (from 101 fewer to 41 more)		CRITICAL
Hospital	length of	stay									1
1 RCTs	not serious	not serious	serious ^a	very serious e	none	104	100	-	MD 0.8 days higher (0.59 lower to 2.19 higher)	⊕⊖⊖⊖ VERY LOW	IMPORTANT
ICU leng	th of stay	1	<u> </u>	<u> </u>	1	1					1
2 RCTs	not serious	not serious	serious ^a	serious ^d	none	154	157	-	MD 0.55 days lower (2 lower to 0.89 higher)		IMPORTANT
Patient c	comfort	1	1								1
4 RCTs	not serious	not serious	serious ^a	not serious	none	207	208	-	SMD 0.23 lower (0.55 lower to 0.09 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
Dyspnea	1	1	1	1							1
4 RCTs	not serious	very serious ^f	serious ^a	serious ^g	none	193	194	-	SMD 0.19 higher (0.01 lower to 0.40 higher)	⊕⊖⊖⊖ VERY LOW	IMPORTANT

PaO2/FiC	02										
3 RCTs	not serious	not serious	serious ^a	not serious	none	215	219	-	MD 43.26 higher (29.48 higher to 57.04 higher)	$\oplus \oplus \oplus \bigcirc \bigcirc$	IMPORTANT
									(MODERATE	
PaO2			8	:			i			:	•
4 RCTs	not	not serious	serious ^a	not serious	none	229	233	-	MD 19.98 mmHg higher	$\oplus \oplus \oplus \bigcirc \bigcirc$	IMPORTANT
	serious								(11.97 higher to 28 higher)	MODERATE	
PCO2				1						!	1
4 RCTs	not	serious ^c	serious ^a	not serious	none	209	211	-	MD 0.45 mmHg lower	$\oplus \oplus \bigcirc \bigcirc$	IMPORTANT
	serious								(1.94 lower to 1.05 higher)	LOW	
Respirate	ory rate		1		1						
5 RCTs	not	serious ^c	serious ^a	not serious	none	302	309	-	MD 0.83 breaths per minute higher	$\oplus \oplus \bigcirc \bigcirc$	IMPORTANT
	serious								(1.04 lower to 2.7 higher)	LOW	

CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference

Explanations

a. Concerns were raised about the short duration of NIV in the study with the largest effects (Frat et al); as well NIV interfaces used (face mask vs. helmet) and use of humidification for secretion clearance during NIV varied between studies. As a result, we rated down for indirectness of the comparator.

b. Optimal information size not met, assuming even a conservative relative risk reduction of 30%; thus we chose to rate down for imprecision, despite a statistically significant reduction in mortality.

c. Substantial heterogeneity (I2>40%) not easily explained by study characteristics.

d. Wide 95% confidence intervals which do not exclude clinically meaningful benefit or harm.

e. Very wide 95% confidence intervals which do not exclude clinically meaningful benefit or harm.

f. Very substantial heterogeneity (I2>80%) with two studies demonstrating opposite effects.

g. We chose not to rate down for imprecision as this was accounted for in considering the very significant inconsistency between the included studies.


1. Mortality (90 day)

	HFN	с	NIV	,		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M–H, Fixed, 95% Cl
2.1.1 Immunocompe	tent							
Frat 2015 Subtotal (95% CI)	9	80 80	19	84 84	60.7% 60.7%		2015	
Total events	9		19					
Heterogeneity: Not ap	plicable							
Test for overall effect:	Z = 1.87	'(P = 0)	.06)					
2.1.2 Immunocompro	omised							
Frat 2017 Subtotal (95% CI)	4	26 26	12	26 26	39.3% 39.3%	• / •	2017	
Total events	4		12					
Heterogeneity: Not ap	plicable							
Test for overall effect:	Z = 2.17	'(P = 0)	.03)					
Total (95% CI)		106		110	100.0%	0.43 [0.24, 0.78]		
Total events	13		31					
Heterogeneity: $Chi^2 =$	0.40, df	= 1 (P	= 0.52);	$I^2 = 0\%$	6			
Test for overall effect:								0.1 0.2 0.5 1 2 5 10 Favours HFNC Favours NIV
Test for subgroup diff	erences:	Chi ² =	0.40, df	= 1 (P	= 0.52),	$l^2 = 0\%$		FAVOUIS FINC FAVOUIS NIV

2. Mortality (early - ICU, hospital, or 28 day)

	HFN	С	NIV	/		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M–H, Fixed, 95% Cl	Year	M–H, Fixed, 95% Cl
2.3.1 Immunocompe	tent							
Frat 2015	8	80	16	84	33.7%	0.53 [0.24, 1.16]	2015	
Shebl 2018	9	34	11	36	23.1%	0.87 [0.41, 1.83]	2018	
Adi 2019 Subtotal (95% CI)	14	94 208	9	94 214	19.4% 76.2%	. ,	2019	
Total events Heterogeneity: Chi ² = Test for overall effect:	,		.,	$l^2 = 45$	5%			
2.3.2 Immunocompr	omised							
Frat 2017 Subtotal (95% CI)	4	26 26	11	26 26	23.8% 23.8%		2017	
Total events Heterogeneity: Not ap Test for overall effect:	•	7 (P = (11					
Total (95% CI)		234		240	100.0%	0.77 [0.52, 1.14]		
Total events Heterogeneity: Chi ² = Test for overall effect: Test for subgroup diff	Z = 1.32	= 3 (P 2 (P = 0	47 = 0.10);).19)	$l^2 = 52$	2%			0.1 0.2 0.5 1 2 5 10 Favours HFNC Favours NIV

3. Intubation



4. Hospital length of stay

	H	IFNC			NIV			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Doshi 2018	6.8	5.7	104	6	4.4	100	100.0%	0.80 [-0.59, 2.19]	
Total (95% CI)			104			100	100.0%	0.80 [-0.59, 2.19]	
Heterogeneity: Not ap Test for overall effect:	•		= 0.26)					-2 -1 0 1 2 Favours HFNC Favours NIV

5. ICU length of stay

	1	HFNC			NIV			Mean Difference			Mean	Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year		IV, Fix	ed, 95%	6 CI	
Frat 2015	10.7	15.8	106	11	11.6	110	15.2%	-0.30 [-4.01, 3.41]	2015			•		
Doshi 2018	3.3	3.7	48	3.9	4.1	47	84.8%	-0.60 [-2.17, 0.97]	2018				-	
Total (95% CI)			154			157	100.0%	-0.55 [-2.00, 0.89]						
Heterogeneity: Chi ² =					: 0%					 -4	-2	0	2	
Test for overall effect:	Z = 0.7	75 (P =	0.45)							-	Favours HFN	C Favo	urs NIV	

6. Patient comfort (various rating systems)

	F	IFNC			NIV			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Schabbauer 2014	2.7	1.8	14	5.4	3.1	14	12.5%	-1.03 [-1.83, -0.24]	2014	
Frat 2015	38	31	106	46	30	110	38.8%	-0.26 [-0.53, 0.01]	2015	
Doshi 2018	2	3	72	2	3.7	69	34.0%	0.00 [-0.33, 0.33]	2018	_ + _
Grieco 2020	5	3	15	5	3	15	14.7%	0.00 [-0.72, 0.72]	2020	
Total (95% CI)			207			208	100.0%	-0.23 [-0.55, 0.09]		
Heterogeneity: Tau ² =	= 0.05; (Chi² =	6.13,	df = 3	(P =	0.11); I	$^{2} = 51\%$			
Test for overall effect:	Z = 1.4	40 (P	= 0.16)						Favours HFNC Favours NIV

7. Dyspnea (various measures, Borg Dyspnea Scale or visual analog scale)

		HFNC			NIV		:	Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Schabbauer 2014	2.9	2.1	13	5	3.3	14	6.7%	-0.73 [-1.51, 0.05]	2014	
Doshi 2018	2.6	2	71	2.2	1.8	71	38.0%	0.21 [-0.12, 0.54]	2018	+=-
Adi 2019	21.7	10.64	94	20.43	11.91	94	50.5%	0.11 [-0.17, 0.40]	2019	
Grieco 2020	8	2.2	15	3	2.2	15	4.7%	2.21 [1.28, 3.15]	2020	
Total (95% CI)			193			194	100.0%	0.19 [-0.01, 0.40]		◆
Heterogeneity: Chi ² = Test for overall effect)001); l ²	² = 87%					-2 -1 0 1 2 Favours HFNC Favours NIV

8. PaO2:FiO2

	H	IFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Frat 2015	130	60	106	186	85	110	49.6%	-56.00 [-75.56, -36.44]	2015	
Adi 2019	271.83	73.63	94	294.19	68.52	94	45.9%	-22.36 [-42.69, -2.03]	2019	
Grieco 2020	138	52.6	15	255	118	15	4.4%	-117.00 [-182.38, -51.62]	2020	
Total (95% CI)			215			219	100.0%	-43.26 [-57.04, -29.48]		•
Heterogeneity: Chi ² =	,				1%					-100 -50 0 50 100
Test for overall effect	Z = 6.15	(P < 0.	00001))						Favours HFNC Favours NIV

9. PaO2

		HFNC			NIV			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Adi 2019	163.1	44.18	94	176.52	41.11	94	43.2%	-13.42 [-25.62, -1.22]	
Frat 2015	90	35	106	111	59	110	38.7%	-21.00 [-33.88, -8.12]	
Grieco 2020	69	21.5	15	108	48.1	15	9.0%	-39.00 [-65.66, -12.34]	
Schabbauer 2014	101	34	14	129	38	14	9.0%	-28.00 [-54.71, -1.29]	
Total (95% CI)			229			233	100.0%	-19.98 [-28.00, -11.97]	•
Heterogeneity: $Chi^2 = 3.44$, df = 3 (P = 0.33); l ² = 13% Test for overall effect: Z = 4.88 (P < 0.00001)									-50 -25 0 25 50
rest for overall effect.	Z = 4.0	0 (P < (.0000.	1)					Favours HFNC Favours NIV

10. PCO2 (most commonly PaCO2)

	I	HFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Schabbauer 2014	37	5	14	39	7	14	11.0%	-2.00 [-6.51, 2.51]	2014	
Frat 2015	35	7	106	35	7	110	64.1%	0.00 [-1.87, 1.87]	2015	
Doshi 2018	46.3	12.7	74	52.5	17.8	72	8.8%	-6.20 [-11.23, -1.17]	2018	
Grieco 2020	33	4.4	15	31	5.9	15	16.1%	2.00 [-1.72, 5.72]	2020	
Total (95% CI)			209			211	100.0%	-0.45 [-1.94, 1.05]		•
Heterogeneity: $Chi^2 = 7.36$, $df = 3$ (P = 0.06); $I^2 = 59\%$									-	
Test for overall effect	Z = 0.5	8 (P =	0.56)							Favours HFNC Favours NIV

11. Respiratory rate

	H	HFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Schabbauer 2014	26	7	14	24	9	14	7.5%	2.00 [-3.97, 7.97]	2014	
Frat 2015	27	7	106	29	7	110	23.9%	-2.00 [-3.87, -0.13]	2015	
Doshi 2018	22.2	4.7	73	22.1	4.8	76	26.0%	0.10 [-1.43, 1.63]	2018	_
Adi 2019	24.51	3.69	94	23	3.61	94	28.6%	1.51 [0.47, 2.55]	2019	- -
Grieco 2020	29	4.4	15	24	5.9	15	14.0%	5.00 [1.28, 8.72]	2020	
Total (95% CI)			302			309	100.0%	0.83 [-1.04, 2.70]		
Heterogeneity: Tau ² =										
Test for overall effect	: Z = 0.8	7 (P =	0.39)							-4 -2 0 2 4 Favours HFNC Favours NIV

Recommendation 4: High-flow nasal cannula (HFNC) vs. conventional oxygen therapy (COT) in post-operative patients

		Certainty a	issessment			№ of pa	tients		Effect		Importance
№ of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	HFNC	СОТ	Relative (95% Cl)	Absolute (95% Cl)	Certainty	
Mortality ·	- Post-opera	ative	!	1	· · · · ·		I			-	
7 RCTs	not serious	not serious	not serious	serious ^a	none	4/526 (0.8%)	7/523 (1.3%)	RR 0.64 (0.19 to 2.14)	5 fewer per 1,000 (from 11 fewer to 15 more)	⊕⊕⊕⊖ MODERATE	CRITICAL
Re-intuba	tion - Post-	operative	<u> </u>	<u> </u>							
8 RCTs	serious ^b	not serious	not serious	serious ^a	none	14/609 (2.3%)	22/601 (3.7%)	RR 0.66 (0.23 to 1.91)	12 fewer per 1,000 (from 28 fewer to 33 more)		CRITICAL
Escalate t	to NIV - Pos	t-op	1		II		I				1
7 RCTs	serious ^b	serious ^c	not serious	serious ^a	none	52/558 (9.3%)	65/552 (11.8%)	RR 0.77 (0.42 to 1.40)	27 fewer per 1,000 (from 68 fewer to 47 more)	⊕⊖⊖⊖ VERY LOW	CRITICAL
ICU Lengt	th of Stay - I	Post-op								_	
10 RCTs	not serious	not serious	not serious	not serious	none	707	709	-	MD 0.02 higher (0.09 lower to 0.13 higher)	⊕⊕⊕⊕ HIGH	CRITICAL
Hospital L	_ength of St	ay - Post-op									
11 RCTs	not serious	not serious	not serious	not serious	none	639	655	-	MD 0.47 lower (0.83 lower to 0.11 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
Comfort -	Post-op										
6 RCTs	not serious	very serious ^d	not serious	not serious ^e	none	413	415	-	SMD 0.54 lower (1.12 lower to 0.05 higher)		IMPORTANT
PaO2 - Po	ost-op			1							
2 RCTs	not serious	not serious	not serious	not serious	none	158	162	-	MD 6.2 lower (8.82 lower to 3.58 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
PCO2 - Po	ost-Op										

Recommendation 4: High-flow nasal cannula (HFNC) vs. conventional oxygen therapy (COT) in post-operative patients

5 RCTs	not serious	not serious ^f	not serious	not serious	none	284	285	-	MD 1.9 lower (4.18 lower to 0.38 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
PaO2:FiO	2 - Post-op										
4 RCTs	not serious	not serious ^f	not serious	not serious	none	159	142	-	MD 34.89 lower (84.96 lower to 15.19 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
Respirato	ry Rate - Po	st-op	1								
3 RCTs	not serious	serious °	not serious	not serious	none	178	167	-	MD 0.14 lower (0.83 lower to 0.54 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT

CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference

Explanations

a. Wide 95% confidence intervals which do not exclude clinically important benefit or harm.

b. Lack of blinding may have resulted in bias from co-intervention as many trials did not have protocols for escalation of respiratory support.

c. Significant heterogeneity (I2 >50%) with point estimates on both sides of the line of no effect and limited overlap of 95% confidence intervals.

d. Very significant heterogeneity (12 >90%) with point estimates on both sides of the line of no effect and limited overlap of 95% confidence intervals.

e. We did not rate down for imprecision as this is accounted for in rating down twice for inconsistency.

f. Although there is significant heterogeneity (I2 >90%) the discrepancies in absolute effect sizes are of questionable significance

1. Mortality

	HFN	С	CO	г		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M–H, Random, 95% Cl	
Futier 2016	2	108	3	112	46.0%	0.69 [0.12, 4.06]			
Parke 2013	1	169	1	171	18.9%	1.01 [0.06, 16.05]			
Pennisi 2019	0	47	0	48		Not estimable			
Sahin 2018	0	50	2	50	15.9%	0.20 [0.01, 4.06]			
Vourc'h 2020	0	47	0	43		Not estimable			
Yu 2017	0	56	0	54		Not estimable			
Zochios 2018	1	49	1	45	19.2%	0.92 [0.06, 14.25]			
Total (95% CI)		526		523	100.0%	0.64 [0.19, 2.14]			
Total events	4		7					_	
Heterogeneity: Tau ² =	= 0.00; Cł	$ni^2 = 0.$	76, df =	3 (P =	0.86); I ²	= 0%			100
Test for overall effect	Z = 0.72	2 (P = 0)).47)				0.01	0.1 1 10 Favours HFNC Favours COT	100

2. Re-intubation

	HFN	С	co	Г		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Parke 2013	2	169	0	171	9.1%	5.06 [0.24, 104.59]	2013	
Corley 2015	0	81	2	74	9.1%	0.18 [0.01, 3.75]	2015	
Futier 2016	7	108	4	112	23.7%	1.81 [0.55, 6.02]	2016	
Yu 2017	0	56	5	54	9.8%	0.09 [0.00, 1.55]	2017	
Sahin 2018	0	50	4	50	9.7%	0.11 [0.01, 2.01]	2018	
Zochios 2018	1	51	5	49	14.5%	0.19 [0.02, 1.59]	2018	
Pennisi 2019	1	47	1	48	10.5%	1.02 [0.07, 15.86]	2019	
Vourc'h 2020	3	47	1	43	13.7%	2.74 [0.30, 25.40]	2020	
Total (95% CI)		609		601	100.0%	0.66 [0.23, 1.91]		
Total events	14		22					
Heterogeneity: Tau ² =	0.88; Cl	$hi^2 = 11$	L.51, df =	= 7 (P =	= 0.12); l ⁱ	$^{2} = 39\%$		0.005 0.1 1 10 200
Test for overall effect:	Z = 0.77	7 (P = 0)).44)					Favours HFNC Favours COT

Recommendation 4: High-flow nasal cannula (HFNC) vs. conventional oxygen therapy (COT) in post-operative patients

3. Escalation to NIV

	HFNC COT					Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Corley 2015	3	81	2	74	8.3%	1.37 [0.24, 7.97]	
Futier 2016	18	108	11	112	20.4%	1.70 [0.84, 3.42]	+
Parke 2013	9	169	5	171	14.9%	1.82 [0.62, 5.32]	
Pennisi 2019	1	47	3	48	5.8%	0.34 [0.04, 3.16]	
Sahin 2018	6	50	11	50	17.1%	0.55 [0.22, 1.36]	
Vourc'h 2020	13	47	24	43	23.0%	0.50 [0.29, 0.84]	
Yu 2017	2	56	9	54	10.4%	0.21 [0.05, 0.95]	
Total (95% CI)		558		552	100.0%	0.77 [0.42, 1.40]	
Total events	52		65				
Heterogeneity: Tau ² =	= 0.34; Cł	$ni^2 = 14$	4.31, df =	= 6 (P =	= 0.03); I	$^{2} = 58\%$	0.05 0.2 1 5 20
Test for overall effect	z = 0.86	5 (P = 0)).39)				Favours HFNC Favours COT

4. ICU length of stay

		HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Parke 2013	1.39	0.95	169	1.2	1	171	24.8%	0.19 [-0.02, 0.40]	2013	
Corley 2015	1.61	1.47	81	1.61	0.995	74	7.4%	0.00 [-0.39, 0.39]	2015	
Futier 2016	6	8.9	108	5	7.4	112	0.2%	1.00 [-1.17, 3.17]	2016	
Yu 2017	3.72	0.56	56	3.64	0.83	54	15.7%	0.08 [-0.19, 0.35]	2017	- - -
Brainard 2017	2	1.2	18	3.2	3.8	26	0.5%	-1.20 [-2.76, 0.36]	2017	
Zochios 2018	1	0.74	49	1	0.74	45	12.5%	0.00 [-0.30, 0.30]	2018	_ + _
Sahin 2018	2.4	0.5	50	2.8	1.7	50	4.8%	-0.40 [-0.89, 0.09]	2018	
Pennisi 2019	1	1.48	47	1	1.48	48	3.3%	0.00 [-0.60, 0.60]	2019	
Twose 2019	1.04	0.34	10	1.22	0.42	10	10.1%	-0.18 [-0.51, 0.15]	2019	
Tatsuishi 2020	1	0.74	72	1	0.74	76	19.2%	0.00 [-0.24, 0.24]	2020	+
Vourc'h 2020	3.3	2.4	47	3.1	1.6	43	1.7%	0.20 [-0.64, 1.04]	2020	
Total (95% CI)			707			709	100.0%	0.02 [-0.09, 0.13]		•
Heterogeneity: Tau ² =	= 0.00; 0	Chi ² =	10.31,	df = 10	0 (P = 0)	.41); I ²	= 3%		_	<u> </u>
Test for overall effect	Z = 0.4	41 (P =	0.68)							-2 -1 U I 2
Test for overall effect	Z = 0.4	41 (P =	= 0.68)							Favours HFNC Favours C

Favours HFNC Favours COT

Recommendation 4: High-flow nasal cannula (HFNC) vs. conventional oxygen therapy (COT) in post-operative patients

5. Hospital length of stay

	I	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	r IV, Random, 95% CI
Parke 2013	11.6	6.6	169	11.4	6.7	171	5.3%	0.20 [-1.21, 1.61]	2013	·
Ansari 2016	2.5	7.4	28	4	12.6	31	0.5%	-1.50 [-6.71, 3.71]	2016	;
Futier 2016	12	9.6	108	11	8.1	112	2.2%	1.00 [-1.35, 3.35]	2016	;
Brainard 2017	6.6	2.1	18	9.5	7	26	1.5%	-2.90 [-5.76, -0.04]	2017	·
Yu 2017	7.41	0.82	56	7.54	0.91	54	22.7%	-0.13 [-0.45, 0.19]	2017	' +
Sahin 2018	6.5	0.7	50	6.9	1.1	50	21.7%	-0.40 [-0.76, -0.04]	2018	; 🗕
Zochios 2018	7	2.2	49	9	6.7	45	2.8%	-2.00 [-4.05, 0.05]	2018	;
Pennisi 2019	6	1.48	47	6	1.48	48	15.8%	0.00 [-0.60, 0.60]	2019) +
Ferrando 2019	3	1	32	4	1	32	18.3%	-1.00 [-1.49, -0.51]	2019) -
Twose 2019	14.5	12.4	10	16	5.2	10	0.2%	-1.50 [-9.83, 6.83]	2019	•
Tatsuishi 2020	8	2.2	72	9	3.7	76	9.1%	-1.00 [-1.97, -0.03]	2020)
Total (95% CI)			639			655	100.0%	-0.47 [-0.83, -0.11]		•
Heterogeneity: Tau ² = Test for overall effect:				df = 10) (P =	0.04); I	$^{2} = 48\%$			
i est isi sverali elleet.			0.01)							Favours HFNC Favours COT

6. Comfort

	H	IFNC			сот			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Tiruvoipati 2010	0.53	1.04	42	0.96	1.42	42	16.9%	-0.34 [-0.77, 0.09]	2010	
Parke 2013	-6.94	2.5	169	-7.78	1.9	171	18.1%	0.38 [0.16, 0.59]	2013	
Rittayamai 2014	1.4	0.9	17	1.9	1.1	17	14.8%	-0.49 [-1.17, 0.20]	2014	
Futier 2016	7.9	2.1	108	8.1	2.4	112	17.9%	-0.09 [-0.35, 0.18]	2016	
Song 2017	3	1.1	30	5	1.5	30	15.7%	-1.50 [-2.08, -0.92]	2017	_
Vourc'h 2020	-4	0.74	47	-3	0.74	43	16.6%	-1.34 [-1.80, -0.88]	2020	_ - _
Total (95% CI)			413			415	100.0%	-0.54 [-1.12, 0.05]		
Heterogeneity: Tau ² =	= 0.47; 0	2hi ² = 2	71.88,	df = 5 (P < 0.	00001)); $I^2 = 93\%$	6		
Test for overall effect	: Z = 1.8	1 (P =	0.07)							Favours HFNC Favours COT

7. PaO2

	н		C	сот			Mean Difference		Mean Differen	ce	
Study or Subgroup	Mean SD Total Mean S				SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 959	% CI
Futier 2016	-89	35	108	-87	32	112	8.7%	-2.00 [-10.87, 6.87]	2016	· · · · · · · · · · · · · · · · · · ·	
Sahin 2018	-106	6.9	50	-99.4	7.1	50	91.3%	-6.60 [-9.34, -3.86]	2018		
Total (95% CI)			158			162	100.0%	-6.20 [-8.82, -3.58]			
Heterogeneity: Tau ² =					(P =)	0.33); I	$^{2} = 0\%$			-10 -5 0	5 10
Test for overall effect:	Z = 4.6	53 (P	< 0.00	001)						Favours HFNC Favou	irs COT

8. PCO2

	1	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Futier 2016	41	7	108	41	6	112	19.9%	0.00 [-1.73, 1.73]	2016	
Sahin 2018	37.9	2.6	50	42.3	2.2	50	21.6%	-4.40 [-5.34, -3.46]	2018	_ _
Pennisi 2019	38.9	3.15	47	40.6	3.89	48	20.6%	-1.70 [-3.12, -0.28]	2019	
Ferrando 2019	37.9	5.6	32	42.3	5.1	32	17.3%	-4.40 [-7.02, -1.78]	2019	
Vourc'h 2020	39.8	3	47	39	3.8	43	20.6%	0.80 [-0.62, 2.22]	2020	
Total (95% CI)			284			285	100.0%	-1.90 [-4.18, 0.38]		
Heterogeneity: Tau ² =	= 6.03; 0	Chi ² =	47.20,	df = 4	(P < 0	.00001); $I^2 = 92$	%		
Test for overall effect	: Z = 1.6	63 (P =	0.10)							Favours HFNC Favours COT

9. PaO2/FiO2

		HFNC		СОТ				Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI Ye	ar IV, Random, 95% CI
Corley 2015	-175.8	96.3791	33	-159.3	96.3791	19	22.0%	-16.50 [-70.90, 37.90] 202	15
Ferrando 2019	-344	104.8	32	-226	66.3	32	24.3%	-118.00 [-160.97, -75.03] 202	19 —
Pennisi 2019	-300	75.2	47	-299	81.3	48	26.5%	-1.00 [-32.48, 30.48] 201	19 —
Vourc'h 2020	-136.5	47	47	-128.1	81.3	43	27.2%	-8.40 [-36.17, 19.37] 202	20
Total (95% CI)			159			142	100.0%	-34.89 [-84.96, 15.19]	
Heterogeneity: Tau ² = Test for overall effect				f = 3 (P -	< 0.0001);	$l^2 = 86$	5%		-100 -50 0 50 100 Favours HFNC Favours COT

10. Respiratory rate

		HFNC			СОТ			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Corley 2015	18.29	2.6017	81	17.85	2.6017	74	33.5%	0.44 [-0.38, 1.26]	2015	
Sahin 2018	19.3	0.9	50	19.5	1.1	50	53.2%	-0.20 [-0.59, 0.19]	2018	
Vourc'h 2020	19.2	4	47	20.6	4.1	43	13.3%	-1.40 [-3.08, 0.28]	2020	
Total (95% CI)			178			167	100.0%	-0.14 [-0.83, 0.54]		-
Heterogeneity: Tau ² =	= 0.19; C	$2hi^2 = 4.1$	8, df =	2 (P =	0.12); I ²	= 52%				
Test for overall effect:	Z = 0.4	1 (P = 0.	68)							Favours HFNC Favours COT

		Certainty assessment bias Inconsistency Indirectness Impre-				Nº of p	atients		Effect		
Nº of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	HFNC	NIV	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
Mortality	- Post-op										1
1 RCT	not serious	not serious	not serious ^a	very serious b	none	28/414 (6.8%)	23/416 (5.5%)	RR 1.22 (0.72 to 2.09)	12 more per 1,000 (from 15 fewer to 60 more)		CRITICAL
Re-intuba	ation - Post-op										
1 RCT	not serious ^c	not serious	not serious ^a	serious ^d	none	58/414 (14.0%)	57/416 (13.7%)	RR 1.02 (0.73 to 1.44)	3 more per 1,000 (from 37 fewer to 60 more)	⊕⊕⊕⊖ MODERATE	CRITICAL
ICU lengt	th of stay - Post	-ор									
1 RCT	not serious	not serious	not serious ^a	not serious ^e	none	414	416	-	MD 0 days (0.6 lower to 0.6 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
Hospital	length of stay -	Post-op									
1 RCT	not serious	not serious	not serious ^a	serious ^d	none	414	416	-	MD 1 lower (2.21 lower to 0.21 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
PCO2 - P	ost-op										
1 RCT	not serious	not serious	not serious ^a	not serious	none	414	416	-	MD 1.1 mmHg lower (2.02 lower to 0.18 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
PaO2:FIC	02 - Post-op										
1 RCT	not serious	not serious	not serious ^a	not serious	none	414	416	-	MD 63 lower (80 lower to 46 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
Respirate	ory Rate - Post-	ор									
1 RCT	not serious	not serious	not serious ^a	not serious	none	414	416	-	MD 0.9 RPM lower (1.81 lower to 0.01 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT

CI: Confidence interval; RR: Risk ratio; MD: Mean difference

Explanations

a. Single trial recruited patients after cardiothoracic surgery only; patients with other types of surgery are not represented in this evidence.


b. Very wide 95% confidence interval does not exclude moderate harm or small benefit of HFNC.

c. Single included trial used pre-specified criteria for escalation of respiratory support, including intubation.

d. Wide 95% confidence interval does not exclude clinically meaningful benefit or harm.

e. Though not statistically significant, the 95% confidence intervals likely exclude a meaningful benefit (less than 1 day difference).

1. Mortality



	HFN	С	NIV	/		Risk Ratio			Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M–H, I	Random, 9	5% CI	
Stephan 2015	58	414	57	416		1.02 [0.73, 1.44]					
							L				
							0.5	0.7	1	1.5	2
								Favours H	IFNC Favou	ırs NIV	

3. ICU length of stay

	н	IFNC			NIV			Mean Difference		Mea	an Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Ra	andom, 95	% CI	
Stephan 2015	6	4.4	414	6	4.4	416		0.00 [-0.60, 0.60]					
									-1	-0.5	0	0.5	1
										Favours H	FNC Favo	urs NIV	


4. Hospital length of stay

	HFNC				NIV			Mean Difference			Mea	n Differe	nce	
Study or Subgroup	Mean	Mean SD Total Mea			SD	Total	Weight	IV, Fixed, 95% CI	Year		IV, F	ixed, 95%	6 CI	
Stephan 2015				8.1	416		-1.00 [-2.21, 0.21]	2015						
									-	-2	-1	0	i	2
								Favours HI	NC Favo	urs NIV				


5. PCO2

	н	IFNC			NIV			Mean Difference		Mean	Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI		IV, Fi	xed, 95	% CI	
Stephan 2015	38.2	6.2	414	39.3	7.3	416		-1.10 [-2.02, -0.18]			-		1
									-2	-1	Ó	1	2
										Favours HF	NC Fav	ours NIV	

6. PaO2/FiO2



7. Respiratory rate



		Certainty a	ssessment			Nº of patients Effect					
№ of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	HFNC	СОТ	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
Mortality											
9 RCTs	not serious	not serious	not serious	serious ^a	none	42/503 (8.3%)	41/495 (8.3%)	RR 1.01 (0.68 to 1.52)	1 more per 1,000 (from 27 fewer to 43 more)		CRITICAL
Re-intuba	tion	1	1	!				1	1		
10 RCTs	serious ^b	not serious	not serious	not serious ^c	none	42/563 (7.5%)	75/564 (13.3%)	RR 0.62 (0.38 to 1.01)	51 fewer per 1,000 (from 82 fewer to 1 more)		CRITICAL
Escalate t	to NIV	1		1				1			
6 RCTs	serious ^b	not serious	not serious	not serious	none	15/260 (5.8%)	40/265 (15.1%)	RR 0.38 (0.17 to 0.85)	94 fewer per 1,000 (from 125 fewer to 23 fewer)	⊕⊕⊕⊖ MODERATE	CRITICAL
ICU Lengt	th of Stay	1	<u> </u>					1			
6 RCTs	not serious	not serious	not serious	not serious ^c	none	485	487	-	MD 0.29 higher (0.27 lower to 0.85 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
Hospital L	_ength of St	tay	<u> </u>					1			
4 RCTs	not serious	serious ^d	not serious	serious ^a	none	424	417	-	MD 1.08 lower (4.83 lower to 2.66 higher)		IMPORTANT
Comfort	1										
3 RCTs	not serious	not serious ^e	not serious	not serious	none	89	89	-	SMD 0.77 lower (1.5 lower to 0.03 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
PaO2											
5 RCTs	not serious	not serious	not serious	not serious	none	165	154	-	MD 7.57 higher (2.68 higher to 12.46 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
PCO2											

7 RCTs	not serious	not serious	not serious	not serious	none	460	446	-	MD 0.15 lower (1.89 lower to 1.58 higher)	⊕⊕⊕ HIGH	IMPORTANT
PaO2:FiO	2										
4 RCTs	not serious	serious ^d	not serious	serious ^a	none	378	383	-	MD 14.13 higher (20.48 lower to 48.75 higher)		IMPORTANT
Respirato	ory Rate										
7 RCTs	not serious	not serious ^f	not serious	not serious	none	213	200	-	MD 1.98 lower (3.9 lower to 0.06 lower)	⊕⊕⊕ HIGH	IMPORTANT

CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference

Explanations

a. Wide 95% confidence intervals do not exclude clinically significant benefit nor harm.

b. Lack of blinding may have resulted in bias from co-intervention, though several trials did have specific criteria for escalation of respiratory support.

c. Though not statistically significant, 95% confidence interval likely excludes a significant differences.

d. Large values of I2 (>70%) with point estimates on both sides of the line of no effect.

e. Significant statistical heterogeneity, however all estimates of effect favour HFNC.

f. Although significant statistical heterogeneity, the absolute differences are of questionable clinical significance.


1. Mortality

	HFN	с	CO	г		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Maggiore 2014	6	53	5	52	13.0%	1.18 [0.38, 3.62]	2014	
Perbet 2014	3	40	4	40	8.0%	0.75 [0.18, 3.14]	2014	
Hernandez (low risk) 2016	10	264	13	263	25.3%	0.77 [0.34, 1.72]	2016	
Fernandez 2017	12	78	12	77	30.4%	0.99 [0.47, 2.06]	2017	+
Arman 2017	0	8	0	7		Not estimable	2017	
Hu 2020	2	29	1	27	3.0%	1.86 [0.18, 19.38]	2020	
Cho 2020	9	31	6	29	20.3%	1.40 [0.57, 3.45]	2020	
Total (95% CI)		503		495	100.0%	1.01 [0.68, 1.52]		•
Total events	42		41					
Heterogeneity: $Tau^2 = 0.00$;	$Chi^2 = 1.$	47, df	= 5 (P =	0.92);	$l^2 = 0\%$			
Test for overall effect: $Z = 0$.		-						0.1 0.2 0.5 1 2 5 10 Favours HFNC Favours COT

2. Re-intubation

	HFN	С	co	г		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Perbet 2014	9	40	10	40	21.1%	0.90 [0.41, 1.98]	2014	
Maggiore 2014	2	53	11	52	9.0%	0.18 [0.04, 0.77]	2014	
Hernandez (low risk) 2016	13	264	32	263	26.6%	0.40 [0.22, 0.75]	2016	_
Song 2017	1	30	3	30	4.4%	0.33 [0.04, 3.03]	2017	· · · · · · · · · · · · · · · · · · ·
Fernandez 2017	9	78	12	77	20.5%	0.74 [0.33, 1.66]	2017	
Arman 2017	0	8	0	7		Not estimable	2017	
Hu 2020	0	29	0	27		Not estimable	2020	
Matsuda 2020	5	30	6	39	14.0%	1.08 [0.37, 3.21]	2020	
Cho 2020	3	31	1	29	4.4%	2.81 [0.31, 25.48]	2020	
Total (95% CI)		563		564	100.0%	0.62 [0.38, 1.01]		•
Total events	42		75					
Heterogeneity: $Tau^2 = 0.13$;	$Chi^2 = 8$.88, df	= 6 (P =	0.18);	$I^2 = 32\%$			
Test for overall effect: $Z = 1$.								0.05 0.2 İ 5 20 Favours HFNC Favours COT

3. Escalation to NIV



4. ICU length of stay

	1	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Maggiore 2014	11.7	10.2	53	10.4	8.5	52	2.4%	1.30 [-2.29, 4.89]	2014	
Hernandez (low risk) 2016	6	4.4	264	6	5.2	263	45.8%	0.00 [-0.82, 0.82]	2016	
Fernandez 2017	12	13.3	78	14	5.9	77	3.0%	-2.00 [-5.23, 1.23]	2017	
Matsuda 2020	4.4	1.8	30	3.8	1.8	39	42.3%	0.60 [-0.26, 1.46]	2020	+=-
Hu 2020	10	4.4	29	9	4.4	27	5.8%	1.00 [-1.31, 3.31]	2020	
Cho 2020	14.7	9.6	31	13.8	15.7	29	0.7%	0.90 [-5.74, 7.54]	2020	
Total (95% CI)			485			487	100.0%	0.29 [-0.27, 0.85]		•
Heterogeneity: $Tau^2 = 0.00$;	$Chi^2 = 3$	3.61, d	df = 5 (P = 0.6	51); I ² =	= 0%				
Test for overall effect: $Z = 1$.02 (P =	0.31)								Favours HFNC Favours COT

5. Hospital length of stay

	I	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Hernandez (low risk) 2016	11	6.7	264	12	7.4	263	42.2%	-1.00 [-2.21, 0.21]	2016	
Fernandez 2017	27	26.7	78	27	21.5	77	15.6%	0.00 [-7.63, 7.63]	2017	
Blaudszun 2017	8.6	4.3	51	13.4	9.9	48	34.1%	-4.80 [-7.84, -1.76]	2017	
Cho 2020	37.7	25.8	31	25.7	20.9	29	8.1%	12.00 [0.15, 23.85]	2020	
Total (95% CI)			424			417	100.0%	-1.08 [-4.83, 2.66]		-
Heterogeneity: $Tau^2 = 8.26$;				(P = 0)	.02); I ²	= 71%			-	-20 -10 0 10 20
Test for overall effect: $Z = 0$.57 (P =	0.57)								Favours HFNC Favours COT

6. Comfort

	I	HFNC			сот			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Tiruvoipati 2010	0.53	1.04	42	0.96	1.42	42	36.4%	-0.34 [-0.77, 0.09]	2010	
Rittayamai 2014	1.4	0.9	17	1.9	1.1	17	30.6%	-0.49 [-1.17, 0.20]	2014	
Song 2017	3	1.1	30	5	1.5	30	33.1%	-1.50 [-2.08, -0.92]	2017	_
Total (95% CI)			89			89	100.0%	-0.77 [-1.50, -0.03]		
Heterogeneity: Tau ² = Test for overall effect				df = 2	(P = 0	.005); I	$^{2} = 81\%$			-2 -1 0 1 2 Favours HFNC Favours COT

7. PaO2

	Н	IFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Tiruvoipati 2010	-102.14	40.25	42	-98.35	38.54	42	7.5%	-3.79 [-20.64, 13.06]	2010	
Maggiore 2014	-97.5	29.2	53	-85.4	16.3	52	20.2%	-12.10 [-21.12, -3.08]	2014	
Song 2017	-83.2	10.5	27	-74.5	13.1	19	27.4%	-8.70 [-15.80, -1.60]	2017	
DiMussi 2018	-75.1	6.9	14	-72.9	8.6	14	34.1%	-2.20 [-7.98, 3.58]	2018	
Hu 2020	-102.4	25.4	29	-86.6	26.4	27	10.8%	-15.80 [-29.39, -2.21]	2020	
Total (95% CI)			165			154	100.0%	-7.57 [-12.46, -2.68]		•
Heterogeneity: Tau ² =	,		,	4 (P = 0.	21); $I^2 =$	32%				-20 -10 0 10 20
Test for overall effect:	Z = 3.04	(P = 0.0)	02)							Favours HFNC Favours COT

8. PCO2

	I	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Tiruvoipati 2010	37.53	6.23	42	37.91	6.22	42	20.2%	-0.38 [-3.04, 2.28]	2010	
Maggiore 2014	32.3	7.1	53	36.2	11	52	14.7%	-3.90 [-7.45, -0.35]	2014	_
Hernandez (low risk) 2016	37	8	264	36	6	263	32.5%	1.00 [-0.21, 2.21]	2016	+=-
Song 2017	41.4	6.5	27	42.2	13.1	19	6.2%	-0.80 [-7.18, 5.58]	2017	
DiMussi 2018	49.9	11.9	14	51.8	12.7	14	3.3%	-1.90 [-11.02, 7.22]	2018	
Hu 2020	41.3	7.5	29	37.2	9.6	27	10.6%	4.10 [-0.43, 8.63]	2020	
Cho 2020	35.9	7	31	37.1	8.8	29	12.4%	-1.20 [-5.24, 2.84]	2020	
Total (95% CI)			460			446	100.0%	-0.15 [-1.89, 1.58]		•
Heterogeneity: $Tau^2 = 2.02$;	$Chi^2 = 1$	0.46,	df = 6	(P = 0.2)	11); I ²	= 43%				
Test for overall effect: $Z = 0$.17 (P =	0.86)								-10 -5 0 5 10 Favours HFNC Favours COT

9. PaO2/FiO2

	I	HFNC			сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Maggiore 2014	-313.3	83.8	53	-259.2	110.1	52	24.2%	-54.10 [-91.58, -16.62]	2014	
Hernandez (low risk) 2016	-105	32	264	-108	34	263	33.6%	3.00 [-2.64, 8.64]	2016	-
Cho 2020	-277.1	102.5	31	-314.2	102.1	29	19.3%	37.10 [-14.70, 88.90]	2020	
Matsuda 2020	-264	105	30	-224	53	39	22.9%	-40.00 [-81.09, 1.09]	2020	
Total (95% CI)			378			383	100.0%	-14.13 [-48.75, 20.48]		
Heterogeneity: $Tau^2 = 920.9$ Test for overall effect: $Z = 0$			df = 3	(P = 0.0)	02); I ² =	79%				-100 -50 0 50 100 Favours HFNC Favours COT

10. Respiratory rate

	H	HFNC		(сот			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Tiruvoipati 2010	18.68	5.51	42	19.68	6.5	42	14.0%	-1.00 [-3.58, 1.58]	2010	
Maggiore 2014	21	4	53	26	4.3	52	16.6%	-5.00 [-6.59, -3.41]	2014	_
Rittayamai 2014	19.8	3.2	17	23.1	4.4	17	14.0%	-3.30 [-5.89, -0.71]	2014	
Song 2017	22	4	27	26	4	19	14.6%	-4.00 [-6.35, -1.65]	2017	
DiMussi 2018	20.5	2.9	14	21.4	4	14	14.0%	-0.90 [-3.49, 1.69]	2018	
Hu 2020	21	5	29	22	6	27	13.1%	-1.00 [-3.90, 1.90]	2020	
Cho 2020	22.8	5.9	31	20.7	4.5	29	13.8%	2.10 [-0.54, 4.74]	2020	
Total (95% CI)			213			200	100.0%	-1.98 [-3.90, -0.06]		
Heterogeneity: Tau ² =	= 5.11; C	$hi^2 = 2$	26.84,	df = 6 (P = 0	.0002)	; $I^2 = 78\%$			
Test for overall effect:	Z = 2.0	3 (P =	0.04)							Favours HFNC Favours COT

		Certainty a	ssessment			Nº of p	atients		Effect		
Nº of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other	HFNC	NIV	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
Mortality	- General IC	U		4		•					-
5 RCTs	not serious	not serious	not serious	serious ^a	none	111/729 (15.2%)	112/784 (14.3%)	RR 1.07 (0.84 to 1.36)	10 more per 1,000 (from 23 fewer to 51 more)	⊕⊕⊕⊖ MODERATE	CRITICAL
Re-intuba	ation - Gene	ral ICU		1							
5 RCTs	not serious ^b	not serious	not serious	serious	none	139/746 (18.6%)	115/803 (14.3%)	RR 1.31 (1.04 to 1.64)	44 more per 1,000 (from 6 more to 92 more)	⊕⊕⊕⊕ HIGH	CRITICAL
ICU lengt	th of stay - (General ICU		1		1			1		_
4 RCTs	not serious	not serious	not serious	not serious	none	658	705	-	MD 1.0 days lower (1.52 lower to 0.47 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
Hospital	length of st	ay - General ICU		1		1			1		
3 RCTs	not serious	not serious	not serious	not serious	none	636	695	-	MD 1.44 days lower (2.63 lower to 0.25 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
Comfort	- General IC	U	1								_
4 RCTs	not serious	not serious	not serious	not serious	none	85	79	-	SMD 0.73 SD lower (0.98 lower to 0.49 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
PCO2 - G	eneral ICU			I		1					
3 RCTs	not serious	not serious	not serious	not serious	none	356	376	-	MD 1.01 mmHg lower (1.47 lower to 0.55 lower)	⊕⊕⊕⊕ HIGH	IMPORTANT
PaO2:FIC)2 - General	ICU									
3 RCTs	not serious	not serious	not serious	not serious ^c	none	356	376	-	MD 3.86 higher (0.39 higher to 7.34 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
Respirate	ory Rate - G	eneral ICU									
2 RCTs	not serious	not serious ^d	not serious	not serious ^c	none	66	62	-	MD 0.59 respirations per minute lower (2.48 lower to 1.29 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT

CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference

Explanations

- a. Wide 95% confidence intervals do not exclude the possibility of meaningful benefit nor harm.
- b. Lack of blinding may have resulted in bias from co-intervention, though most trials did have specific criteria for escalation of respiratory support, including intubation.
- c. Though not statistically significant, 95% confidence interval likely excludes a meaningful difference.
- d. Statistically significant statistical heterogeneity, but considerable overlap of confidence intervals.

1. Mortality

	HFN	С	NIV	/		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% Cl
Hernandez (high risk) 2016	59	290	56	314	53.6%	1.14 [0.82, 1.59]	2016	
Theerawit 2020	7	71	7	69	5.9%	0.97 [0.36, 2.63]	2017	
Jing 2018	5	22	5	20	5.0%	0.91 [0.31, 2.68]	2018	
Thille 2019	33	302	39	339	30.4%	0.95 [0.61, 1.47]	2019	
Tan 2020	7	44	5	42	5.1%	1.34 [0.46, 3.88]	2020	
Total (95% CI)		729		784	100.0%	1.07 [0.84, 1.36]		
Total events	111		112					
Heterogeneity: $Tau^2 = 0.00$; 0	$Chi^2 = 0.7$	72, df =	= 4 (P =	0.95); I	$^{2} = 0\%$		_	
Test for overall effect: $Z = 0.5$	52 (P = 0)	.61)						0.5 0.7 1 1.5 2 Favours HFNC Favours NIV

2. Re-intubation

	HFNC		NIV			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Hernandez (high risk) 2016	66	290	60	314	52.3%	1.19 [0.87, 1.63]	2016	
Theerawit 2020	5	71	6	69	3.9%	0.81 [0.26, 2.53]	2017	
Guoqiang 2018	1	17	1	19	0.7%	1.12 [0.08, 16.52]	2018	· · · · · · · · · · · · · · · · · · ·
Jing 2018	2	22	1	20	0.9%	1.82 [0.18, 18.55]	2018	· · · · · · · · · · · · · · · · · · ·
Thille 2019	59	302	41	339	37.6%	1.62 [1.12, 2.33]	2019	- -
Tan 2020	6	44	6	42	4.6%	0.95 [0.33, 2.73]	2020	
Total (95% CI)		746		803	100.0%	1.31 [1.04, 1.64]		◆
Total events	139		115					
Heterogeneity: $Tau^2 = 0.00$;	$Chi^2 = 2.7$	73, df =	= 5 (P =	0.74); I	$^{2} = 0\%$			0.05 0.2 1 5 20
Test for overall effect: $Z = 2.3$	33 (P = 0)	.02)						Favours HFNC Favours NIV

3. ICU length of stay

	F	IFNC		NIV				Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Hernandez (high risk) 2016	3	3.7	290	4	5.2	314	54.4%	-1.00 [-1.72, -0.28]	2016	
Jing 2018	8.5	3.5	22	9.4	4.8	20	4.2%	-0.90 [-3.46, 1.66]	2018	
Thille 2019	11	5.9	302	12	5.9	339	33.3%	-1.00 [-1.92, -0.08]	2019	
Tan 2020	7.5	3	44	8.5	4.7	32	8.1%	-1.00 [-2.85, 0.85]	2020	
Total (95% CI)			658			705	100.0%	-1.00 [-1.52, -0.47]		•
Heterogeneity: Tau ² = 0.00; Test for overall effect: Z = 3.			(P = 1.0	00); I	$^{2} = 0\%$				-2 -1 0 1 2 Favours HFNC Favours NIV	

4. Hospital length of stay

	HFN				NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Hernandez (high risk) 2016	23	23.7	290	26	15.6	314	13.6%	-3.00 [-6.23, 0.23]	2016	
Thille 2019	23	17.8	302	25	20	339	16.5%	-2.00 [-4.93, 0.93]	2019	
Tan 2020	10	2.7	44	11	3.9	42	69.9%	-1.00 [-2.42, 0.42]	2020	
Total (95% CI)			636			695	100.0%	-1.44 [-2.63, -0.25]		•
Heterogeneity: Chi ² = 1.40, c Test for overall effect: Z = 2.2			0); I ² =	0%						-4 -2 0 2 4 Favours HFNC Favours NIV

5. Comfort

	HFNC							Std. Mean Difference	Std. Mean Difference
Study or Subgroup	r Subgroup Mean SD Tota				SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Guoqiang 2018	-6	3	19	-4	2.2	17	12.7%	-0.74 [-1.42, -0.06]	
Jing 2018	3.6	1.9	22	5.2	2.3	20	14.7%	-0.75 [-1.38, -0.12]	
Tan 2020	-7	1.5	44	-5	2.2	42	27.1%	-1.06 [-1.51, -0.60]	-
Theerawit 2020	2.8	1.8	71	3.8	1.9	69	45.4%	-0.54 [-0.88, -0.20]	
Total (95% CI)			156			148	100.0%	-0.73 [-0.98, -0.49]	◆
Heterogeneity: Tau ² =	= 0.01; 0	Chi² =	= 3.26,	df = 3	(P =	0.35); I	$ ^2 = 8\%$		
Test for overall effect	Test for overall effect: $Z = 5.82$ (P < 0.00001)								Favours HFNC Favours NIV

6. Dyspnea

	HFNC		NIV				Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI			
Tan 2020	3	1.5	44	2	0.74	42		1.00 [0.50, 1.50]	-1 -0.5 0 0.5 1 Favours HFNC Favours NIV			

8. PCO2

	н	IFNC		NIV				Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Hernandez (high risk) 2016	46	3.1	290	47	2.8	314	96.2%	-1.00 [-1.47, -0.53]	2016	
Jing 2018	56.9	10	22	61.5	16.3	20	0.3%	-4.60 [-12.88, 3.68]	2018	
Tan 2020	51	6.5	44	52	5.2	42	3.5%	-1.00 [-3.48, 1.48]	2020	
Total (95% CI)			356			376	100.0%	-1.01 [-1.47, -0.55]		•
Heterogeneity: $Chi^2 = 0.72$, c Test for overall effect: $Z = 4.2$				= 0%					-	-10 -5 0 5 10 Favours HFNC Favours NIV

9. PaO2/FiO2

	н	FNC		NIV				Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Hernandez (high risk) 2016	-99	2	290	-103	32	314	96.0%	4.00 [0.45, 7.55]	2016	
Jing 2018	-201.2	92.4	22	-257.5	130.7	20	0.3%	56.30 [-12.78, 125.38]	2018	
Tan 2020	-230.3	44	44	-227.2	40.5	42	3.8%	-3.10 [-20.96, 14.76]	2020	
Total (95% CI)			356			376	100.0%	3.86 [0.39, 7.34]		•
Heterogeneity: $Chi^2 = 2.80$, or Test for overall effect: $Z = 2$.); $I^2 = 2$	9%					-	-100 -50 0 50 100 Favours HFNC Favours NIV

9. Respiratory rate

	HFNC							Mean Difference		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI			
Jing 2018	22.4	4.4	22	21	4.5	20	48.9%	1.40 [-1.30, 4.10]	2018				
Tan 2020	19	5.6	44	21.5	6.8	42	51.1%	-2.50 [-5.14, 0.14]	2020				
Total (95% CI)			66			62	100.0%	-0.59 [-2.48, 1.29]					
Heterogeneity: Chi ² =	4.10, d	f = 1	(P = 0	.04); I ²	= 76	%							
Test for overall effect:	Z = 0.6	61 (P	= 0.54)						Favours HFNC Favours NIV			

Recommendation 8: High-flow nasal cannula (HFNC) vs. non-invasive ventilation (NIV) in hypercapnic respiratory failure

		Certai	nty assessment	t		Nº of p	atients		Effect		
№ of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	HFNC	NIV	Relative (95% Cl)	Absolute (95% Cl)	Certainty	Importance
Mortality	- RCTs	!	1	1		1					
4 RCTs	not serious	not serious	not serious ^a	very serious b	none	18/127 (14.2%)	21/123 (17.1%)	RR 0.82 (0.46 to 1.47)	31 fewer per 1,000 (from 92 fewer to 80 more)		CRITICAL
Intubatio	n - RCTs		1	1							1
4 RCTs	not serious	not serious	not serious ^a	very serious b	none	19/141 (13.5%)	23/134 (17.2%)	RR 0.79 (0.46 to 1.35)	36 fewer per 1,000 (from 93 fewer to 60 more)		CRITICAL
ICU lengt	th of stay - I	RCTs	l			1					
3 RCTs	not serious	not serious	not serious	serious ^c	none	118	117	-	MD 0.1 higher (0.73 lower to 0.94 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
Hospital	length of st	ay - RCTs	1	1							1
4 RCTs	not serious	not serious	not serious	serious ^c	none	178	174	-	MD 0.82 days lower (1.83 lower to 0.2 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
Comfort	(lower is be	tter) (Scale from:	0 to 10)								
2 RCTs	not serious ^d	serious ^e	not serious	serious ^f	none	49	52	-	SMD 0.57 SD lower (0.98 lower to 0.16 lower)		IMPORTANT
Dyspnea					1						
3 RCTs	not serious ^d	not serious	not serious	serious ^c	none	77	76	-	MD 0.31 lower (0.94 lower to 0.33 higher)	⊕⊕⊕⊖ MODERATE	IMPORTANT
PaO2/FiC	02 - RCTs (fe	ollow up: mean 6	hours)								

Recommendation 8: High-flow nasal cannula (HFNC) vs. non-invasive ventilation (NIV) in hypercapnic respiratory failure

2 RCTs	not serious	not serious	not serious ^a	not serious	none	44	44	-	MD 0.52 lower (3.59 lower to 2.56 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
PO2 - RC	Ts		1								
3 RCTs	not serious	not serious	not serious	not serious	none	151	109	-	MD 0.32 higher (3.83 lower to 4.47 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT
PCO2 - R	CTs										
6 RCTs	not serious	serious ^e	not serious	serious ^c	none	230	227	-	MD 0.79 mmHg lower (5.19 lower to 3.61 higher)		IMPORTANT
Respirate	ory rate - RC	CTs	1								
5 RCTs	not serious	not serious	not serious	not serious	none	148	144	-	MD 0.40 lower (1.60 lower to 0.8 higher)	⊕⊕⊕⊕ HIGH	IMPORTANT

CI: Confidence interval; RR: Risk ratio; MD: Mean difference; SMD: Standardised mean difference

Explanations

a. NIV settings in comparison group appear to have been reasonable and titrated to patient need in most studies.

b. Very wide 95% confidence intervals resulting in very serious imprecision.

c. Wide 95% confidence intervals which do not rule out significant benefit nor harm.


d. High statistical heterogeneity with study point estimates on opposite sides of the line of no effect.

e. Lack of blinding of patients may result in bias, but given the immediacy of the comfort/discomfort using NIV/HFNC we judge patient assessments of comfort and dyspnea to be of lower risk of bias.

f. Statistically significant but optimal information size not met.

Recommendation 8: High-flow nasal cannula (HFNC) vs. non-invasive ventilation (NIV) in hypercaphic respiratory failure

1. Mortality



2. Intubation

	HFN	С	NIV	/		Risk Ratio			Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year		M–H, Fixed, 95% CI		
Lee 2016	11	44	12	44	50.9%	0.92 [0.45, 1.85]	2016				
Wang 2019	4	23	5	20	22.7%	0.70 [0.22, 2.24]	2019				
Doshi 2020	2	34	5	31	22.2%	0.36 [0.08, 1.75]	2020				
Cortegiani 2020	2	40	1	39	4.3%	1.95 [0.18, 20.64]	2020				
Total (95% CI)		141		134	100.0%	0.79 [0.46, 1.35]					
Total events	19		23						_		
Heterogeneity: Chi ² =	1.72, df	= 3 (P	= 0.63);	$l^2 = 0\%$	6					<u> </u>	- 20
Test for overall effect	Z = 0.86	5 (P = C)).39)					0.05	0.2 1 Favours HFNC Favours N	1IV 2	20

Recommendation 8: High-flow nasal cannula (HFNC) vs. non-invasive ventilation (NIV) in hypercapnic respiratory failure

3. ICU length of stay

	H	HFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Wang 2019	9.09	1.56	23	8.5	1.32	20	57.1%	0.59 [-0.27, 1.45]	2019	
Cong 2019	18.04	6.15	84	18.31	7.01	84	15.6%	-0.27 [-2.26, 1.72]	2019	
Doshi 2020	1.8	1.2	11	2.5	2.3	13	27.3%	-0.70 [-2.14, 0.74]	2020	
Total (95% CI)			118			117	100.0%	0.10 [-0.73, 0.94]		
Heterogeneity: Tau ² = Test for overall effect				f = 2 (P	= 0.29	9); I ² =	20%			-2 -1 0 1 2 Favours HFNC Favours NIV


4. Hospital length of stay

	I	HFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Cong 2019	18.04	6.15	84	18.31	7.01	84	26.0%	-0.27 [-2.26, 1.72]	2019	
Doshi 2020	4.37	3.08	34	5.01	2.39	31	58.0%	-0.64 [-1.97, 0.69]	2020	
Papachatzakis 2020	11.5	8.5	20	11	10.5	20	2.9%	0.50 [-5.42, 6.42]	2020	
Cortegiani 2020	10	7.4	40	13	5.2	39	13.0%	-3.00 [-5.81, -0.19]	2020	
Total (95% CI)			178			174	100.0%	-0.82 [-1.83, 0.20]		•
Heterogeneity: Chi ² =	2.86, df	= 3 (P	P = 0.42	1); $I^2 = 0$	0%				-	
Test for overall effect:	Z = 1.5	8 (P =	0.11)							Favours HFNC Favours NIV

5. Comfort

	ŀ	IFNC			NIV			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Sklar 2018	-6	2.2	15	-7	2.2	15	32.0%	0.44 [-0.28, 1.17]	2018	
Cortegiani 2020	0	1.5	34	2	2.2	37	68.0%	-1.04 [-1.54, -0.54]	2020	
Total (95% CI)			49			52	100.0%	-0.57 [-0.98, -0.16]		•
Heterogeneity: Chi ² =); ² =	= 91%				
Test for overall effect	Z = 2.7	71 (P	= 0.00	7)						Favours HFNC Favours NIV

6. Dyspnea



7. PaO2/FiO2

	н	FNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Lee 2016	-134.8	7.3	44	-134.5	7.5	44	98.9%	-0.30 [-3.39, 2.79]	2016	
Cortegiani 2020	-2.2	62.3	40	17.8	70.8	39	1.1%	-20.00 [-49.44, 9.44]	2020 🕂	<u>_</u>
Total (95% CI)			84			83	100.0%	-0.52 [-3.59, 2.56]		•
Heterogeneity: Chi ² = Test for overall effect	,	,); $I^2 = 41$.%				_	-20 -10 0 10 20 Favours HFNC Favours NIV

8. PO2

		HFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	Year	IV, Fixed, 95% CI
Cong 2019	81.87	15.27	84	82.22	15.64	84	78.7%	-0.35 [-5.02, 4.32]	2019	
Doshi 2020	83	43	27	88	14.8	25	5.8%	-5.00 [-22.23, 12.23]	2020	
Cortegiani 2020	3.1	20.7	40	-2.6	26.6	39	15.5%	5.70 [-4.83, 16.23]	2020	- +
Total (95% CI)			151			148	100.0%	0.32 [-3.83, 4.47]		•
Heterogeneity: Chi ² = Test for overall effect:				b); $I^2 = 0$	%					-50 -25 0 25 50 Favours HFNC Favours NIV

9. PCO2

		HFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	r IV, Random, 95% CI
Lee 2016	56.4	10.1	44	52.6	8.8	44	21.5%	3.80 [-0.16, 7.76]	2016	5
Sklar 2018	53	14	15	54	14	15	11.1%	-1.00 [-11.02, 9.02]	2018	3
Cong 2019	58.87	14.42	84	59.95	13.56	84	21.0%	-1.08 [-5.31, 3.15]	2019)
Doshi 2020	50	11.9	27	57	17	25	13.9%	-7.00 [-15.03, 1.03]	2020)
Cortegiani 2020	64	14.9	40	58.1	12.4	39	17.5%	5.90 [-0.14, 11.94]	2020) – – –
Papachatzakis 2020	50.8	9.4	20	59.6	13.9	20	15.1%	-8.80 [-16.15, -1.45]	2020)
Total (95% CI)			230			227	100.0%	-0.79 [-5.19, 3.61]		
Heterogeneity: Tau ² =	19.33;	$Chi^2 = 1$	5.83, c	df = 5 (F	P = 0.00	(7); $I^2 =$	68%			
Test for overall effect:	Z = 0.3	5 (P = 0)	.72)							-20 -10 0 10 20 Favours HFNC Favours NIV

10. Respiratory rate

	н	IFNC			NIV			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	r IV, Random, 95% CI
Lee 2016	24	5.9	44	24	5.4	44	25.8%	0.00 [-2.36, 2.36]	2016	5
Sklar 2018	18	5.2	15	19	5.9	15	9.1%	-1.00 [-4.98, 2.98]	2018	3
Papachatzakis 2020	15.7	3.5	20	17.3	4.6	20	22.5%	-1.60 [-4.13, 0.93]	2020	
Doshi 2020	21	3.7	29	22	5.2	26	24.8%	-1.00 [-3.41, 1.41]	2020)
Cortegiani 2020	-6	6	40	-7.7	6.9	39	17.7%	1.70 [-1.15, 4.55]	2020	
Total (95% CI)			148			144	100.0%	-0.40 [-1.60, 0.80]		•
Heterogeneity: Tau ² =	0.00; C	:hi² =	3.38,	df = 4 ((P = 0	0.50); l ²	$^{2} = 0\%$			
Test for overall effect:	Z = 0.6	5 (P =	= 0.52)							-10 -5 0 5 10 Favours HFNC Favours NIV

Supplement: Evidence to Decision and Voting Results Supplement

ERS Guidelines: High flow nasal cannula in acute respiratory failure

Authors

Simon Oczkowski^{1,2,*} Begüm Ergan^{3,*} Lieuwe Bos^{4,5}, Michelle Chatwin⁶, Miguel Ferrer⁷, Caesare Gregoretti⁸, Leo Heunks⁹, Jean-Pierre Frat ^{10,11}, Federico

Longhini¹², Stefano Nava¹³, Paolo Navalesi¹⁴, Aylin Ozsancak Uğurlu¹⁵, Lara Pisani¹⁶, Teresa Renda¹⁷, Arnaud Thille¹⁸, João Carlos Winck¹⁹, Wolfram Windisch²⁰,

Thomy Tonia²¹, Jeanette Boyd²² Giovanni Sotigu ²³, Raffaele Scala²⁴

*co-first authors

Affiliations

- 1. Department of Medicine, Division of Critical Care, McMaster University, Hamilton, Ontario, Canada
- 2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
- 3. Department of Pulmonary and Critical Care, Dokuz Eylul University School of Medicine, Izmir, Turkey
- 4. Dept of Intensive Care and Laboratory of Experimental Intensive Care and Anesthesiology (LEICA), Academic Medical Center, Amsterdam
- 5. Respiratory Medicine, Academic Medical Center, Amsterdam, The Netherlands.
- 6. Academic and Clinical Department of Sleep and Breathing and NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, Sydney Street, London, UK.
- 7. Dept of Pneumology, Respiratory Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBERES, Barcelona, Spain.
- 8. Department of Surgical, Oncological and Oral Science, Section of Anesthesia, Analgesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.
- 9. Department of Intensive Care Medicine, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
- 10. Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
- 11. INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.
- 12. Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy
- 13. Dept of Specialistic, Diagnostic and Experimental Medicine, Respiratory and Critical Care, Sant'Orsola Malpighi Hospital, Alma Mater Studiorum, University of Bologna, Bologna, Italy
- 14. Intensive Care Unit, Department of Medical and Surgical Sciences, University Hospital Mater Domini, Magna Graecia University, Catanzaro, Italy.
- 15. Department of Pulmonary Medicine, Baskent University, Istanbul, Turkey.
- 16. Respiratory and Critical Care Unit, Alma Mater Studiorum, University of Bologna, Sant'Orsola Malpighi Hospital, Bologna, Italy.
- 17. Cardiothoracic and Vascular Department, Respiratory and Critical Care Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.
- 18. Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
- 19. Faculdade de Medicina da Universidade do Porto, Portugal.
- 20. Cologne Merheim Hospital, Dept of Pneumology, Kliniken der Stadt Köln, gGmbH, Witten/Herdecke University, Faculty of Health/School of Medicine, Köln, Germany.
- 21. Institute of Social and Preventive Medicine, University of Bern, Switzterland
- 22. European Lung Foundation (ELF), Sheffield, United Kingdom
- 23. Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical, Experimental Sciences, University of Sassari, Sassari, Italy.
- 24. Pulmonology and Respiratory Intensive Care Unit, S Donato Hospital, Arezzo, Italy.

Recommendation: We suggest the use of HFNC over COT in	patients with purely I	hypoxic respiratory failu	re. (conditional recommendation, moderate	certainty).			
Desirable effects	Trivial	Small	Moderate		Large	Varies	Unsure
Undesirable effects	Large	Moderate	Small		Trivial	Varies	Unsure
Certainty of evidence of effects	Very low	Low	Moderate		High	No include	d studies
Variability in values	Important uncer	tainty or variability	Possibly important uncertainty or variability		nportant uncertainty or variability	No important uncert	ainty or variability
Balance of effects	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Unsure
Resources required	Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Unsure
Certainty of evidence of required resources	Very low	Low	Moderate		High	No included	d studies
Cost effectiveness	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studies
Equity	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Unsure
Acceptability	No	Probably no	Probably yes		Yes	Varies	Unsure
Feasibility	No	Probably no	Probably yes		Yes	Varies	Unsure
Recommendation and voting results							
Strong recommendation for comparison over intervention		commendation for over intervention	Conditional recommendation for either the intervention or the comparison	interventio	recommendation for n over comparison	Strong recommendation for intervention over comparison	
			1 votes (5%)	16 י	votes (84%)	2 votes (11%)	
Panel comments							

Question 2: Should HFNC or NIV be used t	for acute hypoxic re	spiratory failure?					
Recommendation: We suggest the use of HFNC over NIV in pur	ely hypoxic respirator	ry failure. (conditional re	ecommendation, low certainty)				
Desirable effects	Trivial	Small	Moderate	Larg	e	Varies	Don't know
Undesirable effects	Large	Moderate	Small	Trivi	al	Varies	Don't know
Certainty of evidence of effects	Very low	Low	Moderate	Hig	h	No included stud	lies
Variability in values	Important uncer	tainty or variability	Possibly important uncertainty or variability	Probably no impor or varia		No important uncertainty	or variability
Balance of effects	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Don't know
Resources required	Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Don't know
Certainty of evidence of required resources	Very low	Low	Moderate	Hig	h	No included stud	lies
Cost effectiveness	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studies
Equity	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
Acceptability	No	Probably no	Probably yes	Yes	5	Varies	Don't know
Feasibility	No	Probably no	Probably yes	Yes	3	Varies	Don't know
Recommendation and voting results							
Strong recommendation for comparison over intervention		commendation for over intervention	Conditional recommendation for either the intervention or the comparison	Conditional recon intervention ove		Strong recommendation for intervention over comparison	No recommendation
			4 votes (21%)	13 votes	(68%)	2 votes (11%)	
Panel comments							
Depends on local expertise and patient tolera starting to use HFNO. HFNC appears more comfortable, easier to so		one approach may be i	nferior to having both available and trialing v	which one works best	for the individual p	patient. If a unit needs to start using e	either; preference for

Question 3: Should HFNC or COT be used during breaks from NIV in patients with acute hypoxic respiratory failure?

Recommendation: We suggest the use of HENC over COT during breaks from NIV in patients with acute hypoxic respiratory failure (conditional recommendation, low certainty)

Desirable effects	Trivial	Small	Moderate	Larg	e	Varies	Don't know
				Earg	•	Valioo	Bontikilow
Undesirable effects	Large	Moderate	Small	Trivi	al	Varies	Don't know
Certainty of evidence of effects	Very low	Low	Moderate	Higl	ו	No included stud	lies
Variability in values	Important uncer	tainty or variability	Possibly important uncertainty or variability	Probably no impor or varia		No important uncertainty	or variability
Balance of effects	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Don't know
Resources required	Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Don't know
Certainty of evidence of required resources	Very low	Low	Moderate	Higi	ı	No included stud	lies
Cost effectiveness	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studie
Equity	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
Acceptability	No	Probably no	Probably yes	Yes		Varies	Don't know
Feasibility	No	Probably no	Probably yes	Yes	;	Varies	Don't know
Recommendation and voting results							
Strong recommendation for comparison over intervention		commendation for ver intervention	Conditional recommendation for either the intervention or the comparison	Conditional recon intervention ove		Strong recommendation for intervention over comparison	No recommendation
	1 vo	te (5%)	14 votes (74%)	4 votes	(21%)		
Panel comments							
It seems reasonable to use HFNC vs COT du	ring brooks of NIV/ in	nationto with high inoni	rates, demand as where hypervarie is highl	u dependent en elve	lar collance, but m	nakaa aanaa aiyan maayita of 01	

Recommendation:							
We suggest that either HFNC or COT are ap	propriate to use in po	stoperative patients at	low risk of respiratory complications. (condit	ional recommendation	n, low certainty)		
Desirable effects	Trivial	Small	Moderate	Larg	e	Varies	Don't know
Undesirable effects	Large	Moderate	Small	Trivi	al	Varies	Don't know
Certainty of evidence of effects	Very low	Low	Moderate	Higl	1	No included stud	dies
Variability in values	Important uncer	tainty or variability	Possibly important uncertainty or variability	Probably no impor or varia		No important uncertainty	or variability
Balance of effects	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Don't know
Resources required	Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Don't know
Certainty of evidence of required resources	Very low	Low	Moderate	Higi	1	No included stud	dies
Cost effectiveness	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studie
Equity	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
Acceptability	No	Probably no	Probably yes	Yes		Varies	Don't know
Feasibility	No	Probably no	Probably yes	Yes	i	Varies	Don't know
Recommendation and voting results							
Strong recommendation for comparison over intervention		commendation for over intervention	Conditional recommendation for either the intervention or the comparison	Conditional recon intervention ove		Strong recommendation for intervention over comparison	No recommendation
	1 vo	te (5%)	14 votes (74%)	4 votes	(21%)		
Panel comments				-			

Because many of the studies included heterogeneous patients, finally it is unclear whether HFNC is more effective than COT in some groups of patients (obese, high risk and/or patients undergoing cardiac or thoracic surgery) Reducing escalation is the main argument, even with a low certainty

Recommendation: We suggest the use of either HFNC or NIV	/ in postoperative pat	ients at high risk of resp	iratory complications. (conditional recomm	endation, low cer	tainty).		
Desirable effects	Trivial	Small	Moderate	Large		Varies	Unsure
Undesirable effects	Large	Moderate	Small		Trivial	Varies	Unsure
Certainty of evidence of effects	Very low	Low	Moderate	High		No include	d studies
Variability in values	Important uncer	tainty or variability	Possibly important uncertainty or variability		nportant uncertainty or variability	No important uncert	ainty or variability
Balance of effects	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Unsure
Resources required	Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Unsure
Certainty of evidence of required resources	Very low	Low	Moderate		High	No included studies	
Cost effectiveness	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studies
Equity	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Unsure
Acceptability	No	Probably no	Probably yes	Yes		Varies	Unsure
Feasibility	No	Probably no	Probably yes	Yes		Varies	Unsure
Recommendation and voting results							
Strong recommendation for comparison over intervention	son Conditional recommendation for comparison over intervention		Conditional recommendation for either the intervention or the comparison	Conditional recommendation for intervention over comparison		Strong recommendation for intervention over comparison	
			17 votes (94%) 1 vote (6%)				
Panel comments							

Question 6: Should HFNC or COT be used in nonsurgical patients at low risk of extubation failure?

Recommendation:

We suggest the use of HFNC over COT in non-surgical patients after extubation at low or moderate risk of extubation failure (conditional recommendation, moderate certainty).

	T · · · ·	0 "	N N N				
Desirable effects	Trivial	Small	Moderate	Large		Varies	Don't know
Undesirable effects	Large	Moderate	Small	Trivial		Varies	Don't know
Certainty of evidence of effects	Very low	Low	Moderate	High	n	No included studies	
Variability in values	Important uncer	tainty or variability	Possibly important uncertainty or variability	Probably no impor or varia		No important uncertainty	or variability
Balance of effects	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Don't know
Resources required	Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Don't know
Certainty of evidence of required resources	Very low	Low	Moderate	High		No included studies	
Cost effectiveness	Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studie
Equity	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
Acceptability	No	Probably no	Probably yes	Yes	5	Varies	Don't know
Feasibility	No	Probably no	Probably yes	Yes		Varies	Don't know
Recommendation and voting results				-			
Strong recommendation for comparison over intervention	Conditional recommendation for comparison over intervention		Conditional recommendation for either the intervention or the comparison	Conditional recommendation for intervention over comparison		Strong recommendation for intervention over comparison	No recommendation
			3 votes (16%)	13 votes (68%)		3 votes (16%)	
Panel comments							

Question 7: Should HFNC or NIV be used in nonsurgical patients at high risk of extubation failure?

Recommendation:

We suggest the use of NIV over HFNC after extubation for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV (conditional recommendation, moderate certainty).

Undesirable effectsLargeCertainty of evidence of effectsVery lowVariability in valuesImportant uncertBalance of effectsFavours the comparisonResources requiredLarge costsCertainty of evidence of required resourcesVery lowCost effectivenessFavours the comparisonEquityReducedAcceptabilityNoFeasibilityNo	Moderate Low ainty or variability Probably favours the comparison Moderate costs Low Probably favours the comparison Probably reduced	Small Moderate Possibly important uncertainty or variability Does not favour intervention or comparison Negligible costs or savings Moderate Does not favour intervention or comparison	Trivi Higl Probably no impor or varia Probably favours the intervention Moderate savings Higl Probably favours the intervention	tant uncertainty bility Favours the intervention Large savings		or variability Don't know Don't know	
Variability in values Important uncert Balance of effects Favours the comparison Resources required Large costs Certainty of evidence of required resources Very low Cost effectiveness Favours the comparison Equity Reduced Acceptability No	ainty or variability Probably favours the comparison Moderate costs Low Probably favours the comparison	Possibly important uncertainty or variability Does not favour intervention or comparison Negligible costs or savings Moderate Does not favour intervention or comparison	Probably no impor or varia Probably favours the intervention Moderate savings High Probably favours	tant uncertainty bility Favours the intervention Large savings	No important uncertainty Varies Varies No included stud	or variability Don't know Don't know	
Balance of effects Favours the comparison Resources required Large costs Certainty of evidence of required resources Very low Cost effectiveness Favours the comparison Equity Reduced Acceptability No	Probably favours the comparison Moderate costs Low Probably favours the comparison	variability Does not favour intervention or comparison Negligible costs or savings Moderate Does not favour intervention or comparison	or varia Probably favours the intervention Moderate savings High Probably favours	bility Favours the intervention Large savings	Varies Varies No included stud	Don't know Don't know	
comparison Resources required Large costs Certainty of evidence of required resources Very low Cost effectiveness Favours the comparison Equity Reduced Acceptability No	the comparison Moderate costs Low Probably favours the comparison	comparison Negligible costs or savings Moderate Does not favour intervention or comparison	the intervention Moderate savings High Probably favours	Intervention	Varies No included stud	Don't know	
Certainty of evidence of required resources Very low Cost effectiveness Favours the comparison Equity Reduced Acceptability No	Low Probably favours the comparison	Moderate Does not favour intervention or comparison	Higl Probably favours	1	No included stud		
resources Favours the comparison Equity Reduced Acceptability No	Probably favours the comparison	Does not favour intervention or comparison	Probably favours			lies	
comparison Equity Acceptability	the comparison	comparison		Favours the	Marka a	No included studies	
Acceptability No	Probably reduced	Durkahl an incent			Varies	No included studie	
		Probably no impact	Probably increased	Increased	Varies	Don't know	
Feasibility No	Probably no	Probably yes	Yes		Varies	Don't know	
	Probably no	Probably yes	Yes		Varies	Don't know	
Recommendation and voting results							
5 • • • • • • • • • • • • • • • • • • •	ommendation for ver intervention	Conditional recommendation for either the intervention or the comparison	Conditional recommendation for intervention over comparison		Strong recommendation for intervention over comparison	No recommendatio	
3 votes (18%) 13 vote	13 votes (76%)				1 vote (6%)		

Question 8: Should HFNC or NIV be used in patients with hypercapnic respiratory failure due to COPD?

Recommendation: We suggest a trial of NIV prior to use of HENC in patients with COPD and acute hypercaphic respiratory failure (conditional recommendation, low certainty).

C in patients with COI	,, ,		· ,	,		
Trivial	Small	Moderate	Large		Varies	Don't know
Large	Moderate	Small	Trivial		Varies	Don't know
Very low	Low	Moderate	High		No included studies	
Important uncer	tainty or variability	Possibly important uncertainty or variability			No important uncertainty	or variability
Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	Don't know
Large costs	Moderate costs	Negligible costs or savings	Moderate savings	Large savings	Varies	Don't know
Very low	Low	Moderate	High		No included stud	lies
Favours the comparison	Probably favours the comparison	Does not favour intervention or comparison	Probably favours the intervention	Favours the intervention	Varies	No included studie
Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
No	Probably no	Probably yes	Yes		Varies	Don't know
No	Probably no	Probably yes	Yes		Varies	Don't know
Conditional recommendation for comparison over intervention		Conditional recommendation for either the intervention or the comparison	Conditional recommendation for intervention over comparison		Strong recommendation for intervention over comparison	No recommendatio
13 votes (81%)						
						<u></u>
	Trivial Large Very low Important uncer Favours the comparison Large costs Very low Favours the comparison Reduced No No Conditional rec comparison of	LargeModerateLargeModerateVery lowLowImportant uncertainty or variabilityFavours the comparisonProbably favours the comparisonLarge costsModerate costsVery lowLowFavours the comparisonProbably favours the comparisonReducedProbably reducedNoProbably noNoProbably noConditional recommendation for comparison over intervention	TrivialSmallModerateLargeModerateSmallVery lowLowModerateImportant uncertainty or variabilityPossibly important uncertainty or variabilityFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonLarge costsModerate costsNegligible costs or savingsVery lowLowModerateVery lowLowModerateFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonVery lowLowModerateFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonNoProbably reducedProbably no impactNoProbably noProbably no Probably yesNoProbably noProbably yesConditional recommendation for comparison over interventionConditional recommendation for either the intervention or the comparison	LargeModerateSmallTriviVery lowLowModerateHighImportant uncertainty or variabilityPossibly important uncertainty or variabilityProbably no impor or variabilityFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonProbably favours the interventionLarge costsModerate costsNegligible costs or savingsModerate savingsVery lowLowModerateHighFavours the comparisonProbably favours the comparisonProbably favours the intervention or comparisonProbably favours the interventionVery lowLowModerateHighFavours the comparisonProbably favours the comparisonProbably favours the interventionReducedProbably favours the comparisonDoes not favour intervention or comparisonProbably favours the interventionNoProbably reducedProbably no impactProbably increasedNoProbably noProbably yesYesConditional recommendation for comparison over interventionConditional recommendation for either the intervention or the comparisonConditional recommendation for intervention	LargeModerateSmallTrivialVery lowLowModerateHighImportant uncertainty or variabilityPossibly important uncertainty or variabilityProbably no important uncertainty or variabilityFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonProbably favours the interventionLarge costsModerate costsNegligible costs or savingsModerate savingsLarge savingsVery lowLowModerateHighFavours the comparisonProbably favours the comparisonFavours the interventionFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonProbably favours the interventionFavours the comparisonProbably favours the comparisonDoes not favour intervention or comparisonProbably favours the interventionReducedProbably favours the comparisonProbably no impactProbably favours interventionNoProbably noProbably no impactProbably increasedNoProbably noProbably yesYesConditional recommendation for comparison over interventionConditional recommendation for intervention or the comparisonConditional recommendation for intervention or the comparison	Large Moderate Small Trivial Varies Very low Low Moderate High No included study Important uncertainty or variability Possibly important uncertainty or variability Possibly important uncertainty or variability No important uncertainty or variability No important uncertainty or variability No important uncertainty or variability Favours the comparison Probably favours the comparison Does not favour intervention or comparison Probably favours the intervention Favours the intervention Varies Very low Low Moderate High No included study Very low Low Moderate High No included study Very low Low Moderate High No included study Favours the comparison Probably favours the comparison Does not favour intervention or comparison Probably favours the intervention Varies Favours the comparison Probably favours the comparison Does not favour intervention or comparison Probably favours the intervention Varies Reduced Probably no Probably no impact Probably favours the intervention Vari

Definition of which type of Acute Hypercaphic respiratory failure is mandatory, A COPD patients has nothing to do with an hpercaphic Lenovo hypoxemic patients or a hypercaphic neuromuscolar patients The certainty of evidence regarding the effects of HFNC vs. NIV in hypercaphic failure are very limited, but may be useful in less sick patients or those who cannot tolerate NIV It might be worth modulating the strength of recommendation based on the severity of hypercaphic ARF (eg. severe hypercaphia in COPD, the recommendation should be stronger for NIV)

Supplementary Figure 1: PRISMA Diagram of Included Studies

